Hormone Clinic

Archive for the ‘Hormone Clinic’ Category

Viking Therapeutics (VKTX) Q3 2020 Earnings Call Transcript – Motley Fool

October 29th, 2020

Image source: The Motley Fool.

Viking Therapeutics(NASDAQ:VKTX)Q32020 Earnings CallOct 28, 2020, 4:30 p.m. ET

Operator

Welcome to the Viking Therapeutics 2020 third-quarter financial results conference call. [Operator instructions] As a reminder, this call is being recorded today, October 28, 2020. I would now like to turn the conference over to Viking's Manager of Investor Relations Stephanie Diaz. Please go ahead, Stephanie.

Stephanie Diaz -- Investor Relations Officer

Hello, and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's president and CEO; and Greg Zante, senior vice president of finance. Before we begin, I'd like to caution that comments made during this conference call today, October 28, 2020, will contain forward-looking statements within the meaning of the Securities Act of 1933, concerning the current beliefs of the company, which involve a number of assumptions, risks and uncertainties. Actual results could differ from these statements, and the company undertakes no obligation to revise or update any statement made today.

I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters. I'll now turn the call over to Brian Lian for his initial comments.

Brian Lian -- President and Chief Executive Officer

Thanks, Stephanie, and thanks to everyone listening on the webcast or by phone. Today, we'll provide an overview of our third-quarter financial results, as well as an update on recent progress and developments with our pipeline programs and operations. I will begin with an update on our lead thyroid hormone beta receptor agonist program, VK2809. During the third quarter, we continued enrollment of patients in our Phase 2b VOYAGE study in biopsy-confirmed nonalcoholic steatohepatitis and fibrosis.

As of the end of the quarter, the majority of our U.S. clinical sites were open for patient enrollment, though coronavirus-related disruptions continued to impact site operations. We are currently in the process of expanding the number of clinical sites in the U.S. and internationally, and we continue to expect completion of enrollment in the first half of 2021.

With respect to our second thyroid hormone beta receptor agonist, VK0214, during the third quarter, we achieved a significant milestone by advancing this compound into clinical development. In September, we announced the initiation of a Phase 1 trial to evaluate the safety, tolerability and pharmacokinetic profile of VK0214 in healthy subjects. Following completion of this study, we plan to initiate a Phase 1b study in patients with X-link adrenoleukodystrophy. We are excited to be advancing this important program as patients suffering with X-ALD currently have no approved therapeutic options.

I'll provide additional detail on our development activities after we review our third-quarter financial results. With that, I'll turn the call over to Greg Zante, Viking's senior vice president of finance.

Greg Zante -- Senior Vice President of Finance

Thanks, Brian. In conjunction with my comments, I'd like to recommend that participants refer to Viking's Form 10-Q filing with the Securities and Exchange Commission, which we expect to file later today for additional details. I'll now go over our financial results for the third quarter and first nine months ended September 30, 2020, beginning with the results for the quarter. Our research and development expenses for the three months ended September 30, 2020, were $7.1 million, compared to $5.3 million for the same period in 2019.

The increase was primarily due to increased expenses related to our clinical studies, salaries and benefits and stock-based compensation, partially offset by decreased expenses related to preclinical studies and services provided by third-party consultants. Our general and administrative expenses for the three months ended September 30, 2020, were $2.7 million, compared to $2.2 million for the same period in 2019. The increase was primarily due to increased expenses related to stock-based compensation, salaries and benefits and insurance expenses, partially offset by decreased expenses related to legal services and travel. For the three months ended September 30, 2020, Viking reported a net loss of $9.3 million or $0.13 per share, compared to a net loss of $5.7 million or $0.08 per share in the corresponding period in 2019.

The increase in net loss and net loss per share for the three months ended September 30, 2020, was primarily due to increases in research and development and general and administrative expenses noted previously, as well as decreased interest income due to the decline in interest rates throughout the third quarter of 2020 as compared to prevailing interest rates during the third quarter of 2019. I'll now go over the results for the first nine months of 2020. Our research and development expenses for the nine months ended September 30, 2020, were $22.9 million, compared to $17.1 million for the same period in 2019. The increase was primarily due to increased expenses related to our clinical studies, manufacturing for our drug candidates, salaries and benefits and stock-based compensation, partially offset by decreased expenses related to services provided by third-party consultants and preclinical studies.

Our general and administrative expenses for the nine months ended September 30, 2020, were $8.5 million, compared to $6.7 million for the same period in 2019. The increase was primarily due to increased expenses related to stock-based compensation, salaries and benefits and insurance expenses, partially offset by decreased expenses related to services provided by third-party consultants, professional fees and travel. For the nine months ended September 30, 2020, Viking reported a net loss of $28.5 million or $0.39 per share, compared to a net loss of $18.3 million or $0.25 per share in the corresponding period in 2019. The increase in net loss and net loss per share for the nine months ended September 30, 2020, was primarily due to the increases in research and development and general and administrative expenses noted previously, as well as decreased interest income due to the decline in interest rates throughout the first nine months of 2020 as compared to prevailing interest rates during the first nine months of 2019.

Turning to the balance sheet. At September 30, 2020, Viking held cash, cash equivalents and short-term investments totaling $255.3 million, compared to $275.6 million as of December 31, 2019. This concludes my financial review, and I'll now turn the call back over to Brian.

Brian Lian -- President and Chief Executive Officer

Thanks, Greg. I'll now provide an update on our recent development activities, beginning with our lead program, VK2809 for the treatment of NASH and fibrosis. VK2809 is an orally available small molecule agonist of the thyroid homeowner receptor that possesses selectivity for liver tissue, as well as the beta receptor subtype. Clinical data to date have demonstrated that VK2809 has compelling potency, selectivity, safety and tolerability profile that may provide benefit in a range of metabolic disorders, including NASH.

Our enthusiasm for this program stems in part from the results of our previously completed 12-week Phase 2 trial in nonalcoholic fatty liver disease and hypercholesterolemia. These data demonstrated that patients receiving VK2809 experienced statistically significant reductions in liver fat content, as well as improvements in LDL cholesterol, achieving the study's main efficacy objectives. On exploratory measures, evaluating other plasma lipids, such as triglycerides, apolipoprotein B and lipoprotein (a), treatment with VK2809 also resulted in significant reductions. Importantly, these results were achieved without any serious adverse events being reported among patients receiving VK2809 or placebo.

In the third quarter, additional follow-up data from this trial were presented in an oral presentation at the international liver conference, or EASL. The newly reported data demonstrated that patients treated with VK2809 experienced durable, statistically significant reductions in liver fat content that were maintained at week 16, four weeks after completion of the 12-week treatment period in the study. Specifically, VK2809 treated patients maintained a statistically significant 45% median reduction in liver fat content at week 16, compared to a 19% reduction among patients receiving placebo. Additionally, at week 16, 70% of VK2809-treated patients maintained a response, defined as experiencing a greater than or equal to 30% relative reduction of liver fat content from baseline.

Notably, 100% of patients receiving 5 milligrams of VK2809 dose daily maintained a response at week 16. In addition to these durability results, new analyses of week 12 study results demonstrated significant reductions in liver fat content among patients receiving VK2809 as compared to placebo regardless of the presence of common NASH risk factors, including baseline levels of ALT above the upper limit of normal, a body mass index greater than or equal to 30, hypertension or Hispanic ethnicity. The overall data from this study, including these new findings of durability and efficacy in high-risk subgroups, support the underlying promise of VK2809 for the treatment of NASH and fibrosis. In addition, we believe the broad efficacy observed on key lipid measures may indicate cardiometabolic benefits in this setting, an important advantage as compared to mechanisms that may lead to elevations in lipids known to increase cardiovascular risk.

Based on these positive Phase 2 results, last year, we initiated the Phase 2b trial to assess VK2809 in the setting of NASH. This study called VOYAGE is a randomized, double-blind, placebo-controlled multicenter trial designed to assess the efficacy, safety and tolerability of VK2809 in patients with biopsy-confirmed NASH and fibrosis. The study is targeting enrollment of approximately 340 patients across five treatment arms. The target population includes patients with F2 and F3 fibrosis, as well as up to 25% with F1 fibrosis.

Primary end point of the study will evaluate the change in liver fat content as assessed by magnetic resonance imaging proton density fat fraction from baseline to week 12 in subjects treated with VK2809 as compared to subjects receiving placebo. Secondary objectives include evaluation of histologic changes assessed by hepatic biopsy after 52 weeks of treatment. During the quarter, we continued to enroll patients in the U.S. despite the headwinds created by the COVID pandemic.

The majority of our U.S. sites are open for enrollment, and we expect to open ex U.S. sites imminently. In addition, we plan to add further sites for enrollment with a plan to ultimately list over 90 sites globally.

We expect to complete enrollment in VOYAGE during the first half of 2021. I will now turn to our second clinical program, VK0214, for the potential treatment of X-linked adrenoleukodystrophy, or X-ALD. VK0214, like VK2809 is an orally available small molecule thyroid hormone receptor agonist that possesses selectivity for the beta receptor subtype. In preclinical studies, VK0214 was shown to potently activate thyroid hormone beta receptor, leading to improvement in several in vitro measures that suggest potential benefit in X-ALD.

Additional data from in vivo studies have demonstrated that administration of VK0214 produces a significant and durable reduction of very long-chain fatty acids in both plasma and tissue. In part as a result of these important findings, VK0214 has been granted orphan drug designation by the FDA for the treatment of X-ALD. In the third quarter, we announced the initiation of a Phase 1 first-in-human study of VK0214. This trial is a randomized, double-blind, placebo-controlled, single ascending and multiple ascending dose study in healthy volunteers.

The primary objectives of the study include evaluation of the safety and tolerability of single and multiple oral doses of VK0214, as well as the identification of doses for further clinical development in the setting of X-ALD. Investigators will also assess the pharmacokinetics of VK0214, following single and multiple oral doses. Upon successful completion of the ascending dose trial, we plan to initiate a Phase 1b study of VK0214 in patients with X-ALD. We currently expect this study to begin in the first half of 2021.

With two ongoing clinical programs, it is important to maintain a strong financial position, and we continue to carefully manage our cash resources. As Greg stated during the financial discussion, we ended the third quarter with approximately $255 million in cash, and we believe this balance provides the runway required to complete both ongoing trials, as well as a number of additional clinical milestones. In conclusion, our primary focus in the third quarter was on the continued execution of our two clinical programs. In our 52-week Phase 2b VOYAGE trial evaluating VK2809 in patients with NASH and fibrosis, the majority of our planned clinical sites are open for enrollment, and we plan to open additional sites in the coming months.

We expect to complete enrollment in the first half of 2021. With respect to VK0214 for X-linked adrenoleukodystrophy, we were very pleased in the third quarter to move this important program into the clinic. We are currently executing a Phase 1 single ascending and multiple ascending dose study and plan to initiate a Phase 1b study in patients with X-ALD in the first half of 2021. To support these trials, as well as a number of other key objectives, we continue to judiciously manage our cash balance, which remains strong at $255 million as of the end of the third quarter.

This concludes our prepared comments for today. Thanks again for joining us, and we'll now open the call for questions. Operator?

Operator

Thank you. [Operator instructions] Our first question comes from Joon Lee from Truist Securities. Please go ahead.

Joon Lee -- Truist Securities -- Analyst

Hi, Brian. Thanks for taking -- thanks for the update and taking my question. I have a question on the additional data you presented at EASL, which I think is notable for a more robust liver fat reduction in patients with higher baseline ALT, where the placebo effects were suppressed in the higher ALT group. I'm going to guess that the elevated baseline ALT is more in line with the demographics that you're enrolling in the Phase 2b VOYAGE.

Was the powering of VOYAGE factoring in this data stratification specifically? Or was it based on all the patients -- that effects you saw in all the patients in the earlier study? And the second question is the durability that you saw, 16 weeks, does that change how you might strategize around your Phase 3 development plans, given this durability in terms of the frequency of dosing.

Brian Lian -- President and Chief Executive Officer

Joon, thanks for the questions. As far as the subgroups that we looked at in the 12-week study, that didn't change our powering assumptions for the 52-week study. We were looking at overall assessments on histologic changes for the powering assumptions. We just thought it was really interesting when you look at pretty much every subset that we could identify that might represent higher risk or typical NASH phenotype that there wasn't any difference in efficacy.

And I think we had another slide in there about baseline liver fat as well. And it just seemed to be pretty consistent across ALT, BMI, baseline liver fat, hypertension, all of those factors, baseline glucose as well. But we didn't use that for powering anything. And as far as your second question, what was the second question? Durability.

Yes. No, we just think that that's pretty interesting. It's useful scientific data for understanding the kinetics of liver fat changes. It doesn't feed into our Phase 3 or future development plans, but it is a really interesting finding.

It indicates that you don't necessarily need sustained dosing. You might be able to pursue an intermittent strategy, that type of thing. But it didn't really change anything. We had expected there to be good durability based on the mechanism and the robustness of the initial signal.

Joon Lee -- Truist Securities -- Analyst

Thank you.

Brian Lian -- President and Chief Executive Officer

Thanks, Joon.

Operator

The next question comes from Derek Archila from Stifel. Please go ahead.

Derek Archila -- Stifel Financial Corp. -- Analyst

Hey, guys. And congrats on the progress. Just two from us. Just kind of thoughts on the recruitment right now.

I know you're saying and still guiding to completing enrollment by the first half of 2021. I think having some conversations with some of your competitors, they seem to have more challenges with enrollment. So I just want to get a sense of how much does your time line take into effect for kind of COVID and where we are and some of the kind of worsening conditions in the EU, where I think you're going to potentially open sites. So I just want to get your comments on that.

And then second, just give us a sense of the regulatory pathway in X-linked adrenoleukodystrophy and what that looks like? And could we see data from that Phase 1b study sometime toward the end of 2021? Thanks.

Brian Lian -- President and Chief Executive Officer

Yeah. Thanks, Derek. As far as the enrollment in the Phase 2b study, I don't want to understate the challenges. And so it didn't mean to make it sound like we're having a super easy time with it.

It's really, really difficult. I think it's difficult to cross the board for everybody. But when we look at the site operations, the screening pipeline, that sort of thing, we still think we can do this in the first half of 2021. And that could change if there are statewide lockdowns like we saw earlier this year, but we don't see that right now.

What's really interesting in looking at the individual sites, they're maintaining pretty open operations despite the surges in certain parts of the country. And I think that weighs more on patient psychology than site operations now compared to back in March and April. But it's very, very difficult. And we're still expecting to complete enrollment in the first half of '21, but very, very difficult.

As far as the registration path and X-ALD, we hope to get into patients in the first half of the year that provided we get through the multiple ascending dose portion of the ongoing study. And if things go well, it's possible we'd have data next year. I don't know. It's possible we could be certainly later in the year.

And then we plan to talk to the FDA about what the next steps look like. We would expect the end points and registration to be more functionally oriented, not biomarker oriented, but we won't know for sure until we have those conversations.

Derek Archila -- Stifel Financial Corp. -- Analyst

Terrific. Thanks, and congrats again on the progress.

Brian Lian -- President and Chief Executive Officer

Thanks, Derek.

Operator

The next question comes from Steve Seedhouse from Raymond James. Please go ahead.

Ryan Deschner -- Raymond James -- Analyst

This is Ryan on for Steve Seedhouse. Brian, I'm just wondering if you have a timeline for presenting any additional data from the Phase 2a study. Obviously, after the 16-week study or potentially a publication. And are you guys planning on having -- presenting any data at AASLD this year?

Brian Lian -- President and Chief Executive Officer

Thanks, Ryan. No, we're not going to have anything at AASLD. We do have a manuscript in preparation on the 12-week study. Most of the bigger journals are prioritizing COVID right now.

So it has maybe slowed that process down a little bit, but we do intend to submit that in the relatively near term. As far as additional data, no plans today to have additional data from that study. I think we've presented pretty much everything useful that we could present there, but maybe there could be some more in the publication.

Ryan Deschner -- Raymond James -- Analyst

Thanks, Brian.

Brian Lian -- President and Chief Executive Officer

Thanks.

Operator

The next question comes from Matthew Luchini from BMO. Please go ahead.

Matthew Luchini -- BMO Capital Markets -- Analyst

Hi, guys. Thanks for taking the question, and congrats on the progress. So just a couple from me. I guess, first, on the ex U.S.

sites that are going to be opening up, I think when we last connected on the last quarter update, it sounded like those were perhaps a little bit more near term than just kind of opening up this quarter. So just wondering if there were any bottlenecks there that prevented those sites from actually coming online until it seems like the end of the year? And then secondarily, on 0214, for the SAD/MAD data, should we expect that to -- how should we expect that data to be communicated when it comes out? Would that be just press release? Would -- are you holding that for a medical conference of some sort? Yeah, please, on those two.

Brian Lian -- President and Chief Executive Officer

Sure. Thanks, Matt. So on the ex U.S. side, yes, those have been slower than we had hoped to come online primarily due to administrative items.

We had to submit a couple of documents. We had to correct a couple of typos in one document that required a more substantial resubmission of those documents than we had originally planned. It's just -- but nothing major. It was really pretty minor administrative stuff.

And I don't know, it's hard for us to judge how much of that is just COVID-related with delayed communication time lines between our regulatory liaison and the European regulatory agencies. But that could also play a little bit to those -- the kind of slow time line there. But I would say we'll be opening some European sites here imminently. So I think we're on track there.

As far as the VK0214 SAD and MAD data, we would hope to have some of those results in the first half of the year. And good question on the disclosure strategy, I mean, minimally, a press release, but depending on what the day look like, we might try to submit something to a later conference in 2021. But I think that will be driven on what we see. If there's anything really exciting or interesting, we might want to save that for a conference.

But I would say, minimally a press release though.

Matthew Luchini -- BMO Capital Markets -- Analyst

OK. And then just one last one, if I could, on the numbers. Both operating expenses have been quite flat now through three quarters this year. And I guess we've been expecting perhaps a little bit more of a step-up as things had picked up with the Phase 2b.

So just wondering how should we -- we should be thinking about at least maybe the last quarter of the year? And anything you can say loose or otherwise as we start thinking forward to '21. With that, I'll get back in the queue. Thanks so much.

Greg Zante -- Senior Vice President of Finance

Matt, Greg here. Yes, I think -- yes, they have been a little bit flat, but we do expect them to continue to increase from here as the trial continues along. So I think nothing to read into the flatness through this point. I think it will continue to pick up going forward here.

We always try to be conservative on the estimates, but I think it is certainly going to tick up.

Matthew Luchini -- BMO Capital Markets -- Analyst

OK. Great. Congrats on the progress.

OK. Great. Thanks, guys, for the questions, and congrats on the progress.

Brian Lian -- President and Chief Executive Officer

Thanks, Matt.

Operator

The next question comes from Michael Morabito from Chardan Capital Markets. Please go ahead.

Michael Morabito -- Chardan Capital Markets -- Analyst

Hi, guys. I just had a question here. I wanted to know if there was anything put into place for the VOYAGE trial to track patients who at any point during the trial test positive for a COVID during the trial. And if there's any kind of a protocol that you put in place for what would constitute rationale for excluding patients that have been affected by COVID, do you have anything like that in place?

Brian Lian -- President and Chief Executive Officer

Read more:
Viking Therapeutics (VKTX) Q3 2020 Earnings Call Transcript - Motley Fool

Comments Closed|

Hemodialysis Powder Solution Market Analysis, Technologies & Forecasts to 2028 – The Think Curiouser

October 29th, 2020

The winning Hemodialysis Powder Solution Market report makes available the current and forthcoming technical and financial details of the industry. Few of the chief insights of this business report include; distinct analysis of the market drivers & restraints, major market players involved like industry, detailed analysis of the market segmentation & competitive analysis. It estimates CAGR values in percentages which help to know the rise or fall occurring in the market for particular product for the specific forecast period. Global Hemodialysis Powder Solution Market report also encompasses strategic profiling of key players in the market, systematic analysis of their core competencies & draws a competitive landscape for the market.

Request Sample Report @ https://chronicalmarketresearch.com/request-for-sample-report/26350

The Hemodialysis Powder Solution Market report can be better employed by both traditional and new players in the industry for complete knowhow of the market. The industry analysis report brings into focus important industry trends, market size, market share estimates, and sales volume that assist industry to speculate the strategies to increase return on investment (ROI). Moreover, the market document holds a substantial importance when it is about explaining market definition, classifications, applications and engagements. With the study of competitor analysis conducted in this Hemodialysis Powder Solution Market report, industry can get fluency of the strategies of key players in the market that includes new product launches, expansions, agreements, joint ventures, partnerships, and acquisitions.

Market Analysis: Global Hemodialysis Powder Solution Market

Global Hemodialysis Powder Solution market is rising gradually with a substantial CAGR of XX% in the forecast period of 2019-2026. This rise in market value can be attributed in increase in awareness and concerns regarding the health of patients, increasing prevalence of growth hormone disorders and high expenditure in healthcare sector.

Key Players:

The Key manufacturers that are operating in the global Hemodialysis Powder Solution market are:

Baxter

Rockwell Medical

Fresenius

B. Braun

Renacon Pharma

Chief Medical Supplies

Farmasol

Weigao

Tianjin ever -trust medical

Jiangxi Sanxin Medtec

Competitive Landscape

Request Discount About This Report @ https://chronicalmarketresearch.com/discount-request-on-report/26350

Key Benefits of the report:

-This report provides an extensive analysis of the current and emerging market trends and dynamics in the global Hemodialysis Powder Solution market.

-In-depth analysis is conducted by constructing market estimations for the key market segments between 2020 and 2027.

-This report entails the detailed quantitative analysis of the current market and estimations through 2020-2027, which assists in identifying the prevailing market opportunities.

-Extensive analysis of the market is conducted by following key product positioning and monitoring the top competitors within the market framework

-Comprehensive analysis of all regions is provided that determines the prevailing opportunities in these geographies.

The report segments the Hemodialysis Powder Solution market on the basis of product type, application, and geography. On the basis of product type, it includes plastic bar cable markers, clip-on cable markers, printed adhesive cable markers, and electronic marker. On the basis of application, it is segmented into IT & telecom, energy & utility, manufacturing, construction, and others. Based on geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Following are the segments covered by the report are:

Hemodialysis Concentrates

Hemodialysis Dry Powder

By Application:

Public Hospital

Private Clinic

Nursing Home

Personal Care

Others

Request For Customization About This Report @ https://chronicalmarketresearch.com/request-for-customization/26350

Table of Contents: Hemodialysis Powder Solution Market

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers And Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

Contact Us

Chronical Market Research,

4004 W Lake Sammamish,

Pkway B9 Redmond,

WA 98052 United States.

Tel: +44 115 888 3028

Web: http://www.chronicalmarketresearch.com

About Us

At Chronical Market Research, we understand that the research we provide is only as good as the outcome it inspires. These reports are generated by well-renowned publishers on the basis of the data acquired from an extensive research and credible business statistics. Thats why we are proud to provide the widest range of research products, multilingual 24/7 customer support and dedicated custom research services to deliver the insights you need to achieve your goals. Take a look at few of our aspects that makes Chronical Market Research an asset to your business.

Read more:
Hemodialysis Powder Solution Market Analysis, Technologies & Forecasts to 2028 - The Think Curiouser

Comments Closed|

Dementia and Alzheimers Disease Treatment Market with Current Trends Analysis 2020-2027 – The Think Curiouser

October 29th, 2020

The winning Dementia and Alzheimers Disease Treatment Market report makes available the current and forthcoming technical and financial details of the industry. Few of the chief insights of this business report include; distinct analysis of the market drivers & restraints, major market players involved like industry, detailed analysis of the market segmentation & competitive analysis. It estimates CAGR values in percentages which help to know the rise or fall occurring in the market for particular product for the specific forecast period. Global Dementia and Alzheimers Disease Treatment Market report also encompasses strategic profiling of key players in the market, systematic analysis of their core competencies & draws a competitive landscape for the market.

Request Sample Report @ https://chronicalmarketresearch.com/request-for-sample-report/25154

The Dementia and Alzheimers Disease Treatment Market report can be better employed by both traditional and new players in the industry for complete knowhow of the market. The industry analysis report brings into focus important industry trends, market size, market share estimates, and sales volume that assist industry to speculate the strategies to increase return on investment (ROI). Moreover, the market document holds a substantial importance when it is about explaining market definition, classifications, applications and engagements. With the study of competitor analysis conducted in this Dementia and Alzheimers Disease Treatment Market report, industry can get fluency of the strategies of key players in the market that includes new product launches, expansions, agreements, joint ventures, partnerships, and acquisitions.

Market Analysis: Global Dementia and Alzheimers Disease Treatment Market

Global Dementia and Alzheimers Disease Treatment market is rising gradually with a substantial CAGR of XX% in the forecast period of 2019-2026. This rise in market value can be attributed in increase in awareness and concerns regarding the health of patients, increasing prevalence of growth hormone disorders and high expenditure in healthcare sector.

The following players are covered in this report:

Novartis

Pfizer, Inc.

AbbVie Inc.

Allergan plc

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

AstraZeneca

Biogen

Eisai Co., Ltd.

INmuneBIO

Request Discount About This Report @ https://chronicalmarketresearch.com/discount-request-on-report/25154

Key Benefits of the report:

-This report provides an extensive analysis of the current and emerging market trends and dynamics in the global Dementia and Alzheimers Disease Treatment market.

-In-depth analysis is conducted by constructing market estimations for the key market segments between 2020 and 2027.

-This report entails the detailed quantitative analysis of the current market and estimations through 2020-2027, which assists in identifying the prevailing market opportunities.

-Extensive analysis of the market is conducted by following key product positioning and monitoring the top competitors within the market framework

-Comprehensive analysis of all regions is provided that determines the prevailing opportunities in these geographies.

The report segments the Dementia and Alzheimers Disease Treatment market on the basis of product type, application, and geography. On the basis of product type, it includes plastic bar cable markers, clip-on cable markers, printed adhesive cable markers, and electronic marker. On the basis of application, it is segmented into IT & telecom, energy & utility, manufacturing, construction, and others. Based on geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Breakdown Data by Type

Cholinesterase Inhibitors

Memantine

Combination Drugs

Dementia and Alzheimers Disease Treatment Breakdown Data by Application

Hospital

Clinic

Request For Customization About This Report @ https://chronicalmarketresearch.com/request-for-customization/25154

Table of Contents: Dementia and Alzheimers Disease Treatment Market

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers And Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

Contact Us

Chronical Market Research,

4004 W Lake Sammamish,

Pkway B9 Redmond,

WA 98052 United States.

Tel: +44 115 888 3028

Web: http://www.chronicalmarketresearch.com

About Us

At Chronical Market Research, we understand that the research we provide is only as good as the outcome it inspires. These reports are generated by well-renowned publishers on the basis of the data acquired from an extensive research and credible business statistics. Thats why we are proud to provide the widest range of research products, multilingual 24/7 customer support and dedicated custom research services to deliver the insights you need to achieve your goals. Take a look at few of our aspects that makes Chronical Market Research an asset to your business.

More:
Dementia and Alzheimers Disease Treatment Market with Current Trends Analysis 2020-2027 - The Think Curiouser

Comments Closed|

Talking taboos around womens health – Kent Online

October 29th, 2020

Brenda Allen faced the fight of her life — breast cancer. She found support in those who have traveled this road before. – darnews.com

October 29th, 2020

By MARK J. SANDERS Contributing Writer

Brenda Allen, her mother, her sister and a first cousin were all diagnosed with breast cancer over a three-year period.

DAR/Paul Davis

Brenda Allen considers herself fortunate to be a successful survivor of breast cancer, and shes using the lessons learned through her path to recovery to make the most of her life every day.

Brenda, 62, is married to Tom Allen, and both of them are well-known and well-loved retired teachers from the Poplar Bluff R-I School District.

Brenda taught in a number of different roles and locations for 34 years, including music at the elementary and fifth and sixth grade school, vocal music director at the junior and senior high, SINGS instructor, grant administrator and administrator at Lake Road Elementary and Poplar Bluff Junior High.

She first learned of her cancer diagnosis seven years ago, in July 2013. While seeing her doctor for an ear infection, she remembered that her mother had recently had a mammogram, so she decided to do the same on that day.

Her mother was also diagnosed with breast cancer, and Brenda said it was a contributing factor in her mothers eventual passing.

After her doctors visit, she left town for a trip, and when she returned home, she found she had received many unanswered calls from Kneibert Clinic.

I was pretty sure the news was not good, she said.

The mammogram revealed a lump that was thought to be contained within a milk duct. She chose to go to the St. Lukes Hospital Womens Center in St. Louis, where she saw the same doctor as her mother for a needle biopsy.

Get your content delivered! SIGN UP for TODAY'S NEWS! Emailed EVERY DAY at 7:00 AM CST

The biopsy verified the cancer diagnosis, and Brenda was scheduled for a lumpectomy. However, the procedure revealed the cancer was not contained and was more invasive than initially detected.

She was away on another trip, this time to Dauphin Island, Alabama, when St. Lukes called with the bad news about the lumpectomy results. When she returned, she underwent a bilateral mastectomy in September 2013.

This time, the results were much more positive. She needed neither chemotherapy nor radiation as a follow-up to the surgery, and her lymph nodes were not affected, either. The only follow-up treatment was hormone therapy for the next five years.

I was very fortunate, she said. Im likely to put some things off, but women need to take their mammograms seriously.

Although she described her recovery from surgery as relatively easy I went back to work a week after she did undergo genetic counseling. Brenda, her mother, her sister and a first cousin were all diagnosed with breast cancer over a three-year period.

In doing extensive research on her family tree, Brenda discovered her mothers aunt and that aunts granddaughter had both died of breast cancer. The granddaughter was only 35 at the time of her passing.

Brenda was tested for all possible genetic markers indicating further risk of future cancer, but they all came back negative. She described this as a big relief not only for her but also for her own daughter and granddaughter.

After five years of follow-up screenings, she was released as cancer-free.

Brendas advice for other women facing their own breast cancer diagnosis is to not go through any of it alone.

Every woman has a friend who has been through this, she said. Brenda had a close friend who had already survived breast cancer, so she called and asked her to be her cancer mentor.

Youre overwhelmed with all the information the doctors give you, and you dont always know what it all means, she said. You need a friend who can walk with you down that road.

One way Brenda was enjoying retirement this year was to hike the Katy Trail in mid-Missouri. She said the experience of losing her own parents, her in-laws, and a close uncle over the past seven years provided strong motivation to stay active and reach for her goals.

Speaking of her loved ones who have passed, she said, They all spoke of things they wanted to do and said, I wish I had done that.

Hiking the Katy Trail was something I always wanted to do, but I still can.

Read the original post:
Brenda Allen faced the fight of her life -- breast cancer. She found support in those who have traveled this road before. - darnews.com

Comments Closed|

Comprehensive Analysis On Endometriosis Market Based On Types And Application – The Think Curiouser

October 29th, 2020

Dataintelo, one of the worlds prominent market research firms has announced a novel report on the Endometriosis market. The report is integrated with imperative insights on the market which will support the clients to make precise business decisions. This research will help both existing and new aspirants for Global Endometriosis Market to figure out and study market requirements, market size, and competition. The report incorporates data regarding the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities, and the threats encountered by key players during the forecast period of 2020-2027.

Request a sample before buying this report @ https://dataintelo.com/request-sample/?reportId=93801

Impact of COVID-19

The report also incorporates the impact of the ongoing global crisis i.e. COVID-19 on the Endometriosis market and explains how the future is going to unfold for the global market. The report also provides an analysis of the effects of the pandemic on the global economy. The outbreak has directly affected production and demand disrupted the demand and supply chain. The report also computes the financial impact on firms and financial markets. Dataintelo has accumulated insights from various delegates of the industry and got involved in the primary and secondary research to offer the clients data & strategies to combat the market challenges during and after the COVID-19 pandemic.

Benefits of buying the report:

Industry experts and research analysts have worked extensively to fabricate the research report which will give that extra edge to your business in the competitive market. The market research report can be customized as per you and your needs. This means that Dataintelo can cover a particular product, application, or can offer a detailed analysis in the report. You can also buy a separate report for a specific region.

You can buy the complete report @ https://dataintelo.com/checkout/?reportId=93801

Some of the major companies that are covered in this report:

AbbVieAstraZenecaBayer HealthCarePfizerAddex TherapeuticsAstellas PharmaDebiopharmElexoPharmEndoCeuticsEuroscreenForendo PharmaKissei PharmaceuticalNeurocrine BiosciencesNippon ShinyakuTakedaBayer AGNeurocrine Biosciences

*Note: Additional companies can be included on request

The market scenario is likely to be fairly competitive. To analyze any market with simplicity the market is fragmented into the following segments:

By Application:

Hospital UseClinic UseOther

By Type:

Gonadotropins Releasing Hormone AgonistsNon-Steroidal Anti-Inflammatory DrugsProgestinOral Contraceptive Pills

By Geographical Regions

Asia Pacific: China, Japan, India, and Rest of Asia PacificEurope: Germany, the UK, France, and Rest of EuropeNorth America: The US, Mexico, and CanadaLatin America: Brazil and Rest of Latin AmericaMiddle East & Africa: GCC Countries and Rest of Middle East & Africa

Segmenting the market into smaller components helps in analyzing the dynamics of the market with more clarity. Another key component that is integrated into the report is the regional analysis to assess the global presence of the Endometriosis market. You can also opt for a yearly subscription of all the updates on the Endometriosis market.

Below is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Endometriosis Market Overview

Global Endometriosis Market Analysis and Forecast by Type

Global Endometriosis Market Analysis and Forecast by Application

Global Endometriosis Market Analysis and Forecast by Sales Channel

Global Endometriosis Market Analysis and Forecast by Region

North America Endometriosis Market Analysis and Forecast

Latin America Endometriosis Market Analysis and Forecast

Europe Endometriosis Market Analysis and Forecast

Asia Pacific Endometriosis Market Analysis and Forecast

Asia Pacific Endometriosis Market Size and Volume Forecast by Application

Middle East & Africa Endometriosis Market Analysis and Forecast

Competition Landscape

If you have any questions on this report, feel free to reach us! @ https://dataintelo.com/enquiry-before-buying/?reportId=93801

About Dataintelo:

Dataintelo has a vast experience in making customized market research reports in a number of industry verticals. Our motto is to provide complete client satisfaction. We cover in-depth market analysis, which consists of stipulating lucrative business strategies, especially for the new entrants and the emerging players of the market. We make sure that each report goes through intensive primary, secondary research, interviews, and consumer surveys before final dispatch.

We invest in our analysts to ensure that we have a full roster of experience and expertise in any field we cover. Our team members are selected for stellar academic records, specializations in technical fields, and exceptional analytical and communication skills. We also offer ongoing training and knowledge sharing to keep our analysts tapped into industry best practices and loaded with information.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario, CA 91764, United States.Phone No: USA: +1 909 545 6473Email: [emailprotected]Website: https://dataintelo

Read the original here:
Comprehensive Analysis On Endometriosis Market Based On Types And Application - The Think Curiouser

Comments Closed|

Light box therapy: How to combat seasonal depression with the power of light – Insider – INSIDER

October 29th, 2020

Light therapy is considered a first-line treatment for seasonal affective disorder (SAD), a type of depression that occurs during the fall and winter. Here's more about this treatment and how to use it effectively.

About 4%-6% of American adults have SAD, which comes on in the fall and winter, and usually abates in the spring and summer. Research has linked SAD to changes in the amount of daylight and found that it's more common in areas that are far from the equator and thus have shorter, darker days in the winter.

"SAD is generally a dip in mood into a depressive state," says Gonzalo Laje, MD, director of Washington Behavioral Medicine Associates, LLC, and clinical associate professor of psychiatry and behavioral sciences at The George Washington University in Washington D.C.

"It is a real thing, and we have a very interesting approach to treatment, not just traditional antidepressants, but also with light therapy," he says.

To understand how light therapy works, it's important to understand the biological causes of SAD. Research shows that people with SAD have three potential biological causes that contribute to their depression during the darker months:

Light therapy can help regulate melatonin and serotonin levels thereby offsetting some of the depressive symptoms associated with SAD.

How light therapy works is that it aims to make up for the bright light that people aren't getting during the winter months, especially in colder, darker climates.

"There's a clear relationship between environmental light sunlight and mood," Laje says. "What light therapy attempts to do is to overcome a little bit of that lack of light with artificial light."

A 2006 double-blind randomized controlled clinical study found that light therapy improved symptoms in 67% of patients, the same amount who saw improvement on the antidepressant fluoxetine, part of the SSRI class of drugs. Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants.

The reason experts think light therapy is so successful is how it regulates serotonin and melatonin production. For example, researchers have found that light therapy can reduce serotonin transporter binding, leaving more of the feel-good serotonin hormone available in the brain.

Scientists have also found that increasing daytime light exposure with artificial lights could reduce daytime melatonin levels in people experiencing SAD.

Simply having a brightly-lit room is not effective light therapy, Laje says. To get the benefits of light therapy, you need to be exposed to a 10,000-lux light box for 20-30 straight minutes each day, according to Mayo Clinic.

For the light therapy to work, Laje says that you need to sit 1.5 to 2 feet from the light box. It will feel slightly uncomfortable because it's so bright.

"It has to be slightly uncomfortable to be effective," he says. "It's very, very bright. You lose efficacy very quickly if you're far away."

The brightness could harm your eyes, however, so you should never look directly at the lamp. He recommends staying engaged while you're sitting near the light box by reading a book or a newspaper.

Since light therapy affects your biological clock, Laje recommends doing it in the morning, and never in the afternoon, since that could disrupt your normal sleep-wake pattern and could make it harder for you to fall asleep that night.

He recommends that patients do 20-30 minutes of light therapy daily, starting in late September or early October and continuing through the winter months.

"While light therapy seems almost trivial, it can cause problems," he says. For example, people with bipolar disorder could become manic and should only use light therapy under the direction of their doctor, he says. That's why it's always important to talk to your doctor and seek their guidance before starting a light therapy regimen.

Light therapy, alone, may work for some people, but sometimes others may also need anti-depressants or counseling, Laje says. If your depression symptoms are not improving or are worsening under your treatment plan, immediately reach out to your doctor.

Because the lamps used in light therapy do not put out UV rays, there is no cancer risk, Laje says.

Light therapy is an effective way of helping to control the symptoms of seasonal affective disorder. The low light of winter can impact serotonin and melatonin levels, leaving you feeling sluggish, tired, or depressed.

Spending 20-30 minutes in front of a very bright lamp of around 10,000 lux units can help overcome SAD symptoms, regulate your circadian clock, and help you feel better during the winter months, Laje says.

"I'm always fascinated by these approaches, that are simple, effective and generally safe," he says. "With light, we can help our mood."

More here:
Light box therapy: How to combat seasonal depression with the power of light - Insider - INSIDER

Comments Closed|

Active Pharmaceutical Ingredients (API) Market : Industry Analysis, Growth rate, and Future Forecast 2020-2026 – Stock Market Vista

October 29th, 2020

Active Pharmaceutical Ingredients (API) market report provides a detailed insight into the global market landscape and has an in-detail evaluation of the key market prospects. Growth dynamics and leading trends and other essential market prospects have been assessed in order to give the clients an in-depth understanding of the Active Pharmaceutical Ingredients (API) market. The report has a detailed forecast up to 2026 and a historical overview of the Active Pharmaceutical Ingredients (API) market.

Key Market Players mentioned are:Teva Active Pharmaceutical Industries LimitedDSMNovartisRocheJohnson & JohnsonDr. Reddy sPfizerBayerBASFCambrexSun Pharmaceutical IndustriesLonza groupBoehringer Ingelheim GmbHAurobindo pharma

The report details and accounts for important and essential factors crucial to mapping a successful business plan and crafting strategies to ensure a profitable growth curve for the Active Pharmaceutical Ingredients (API) Market. Clients can get a detailed assessment of aspects such as revenue, growth, trends, scope, opportunities, risks, etc. to create a much stronger and effective business canvas. Stakeholders as well as the new players in the Active Pharmaceutical Ingredients (API) market can utilize this report and maximize their revenue generation potential and secure dominance in the global Active Pharmaceutical Ingredients (API) Market.

Get Sample PDF Brochure @https://www.reportsintellect.com/sample-request/1303972?RINT

Description:

This report on the Active Pharmaceutical Ingredients (API) market can be a complete guide to navigate our clients through the Active Pharmaceutical Ingredients (API) market and aid you in accordance with all the essential data required to establish dominance or sustain dominance in the Active Pharmaceutical Ingredients (API) market. The analysts have prepared a detailed and descriptive account of the market in the given report.

Clients through this report can strategize an effective and essential business plan and create an extensive business model to sustain over a long period of time. The report utilizes most of the in demand analyses and has been equipped with the most up to date data to give a complete understanding of the Active Pharmaceutical Ingredients (API) market. Business development, opportunities, dynamics, and expansion all can be navigated through the use of this latest report on the Active Pharmaceutical Ingredients (API) market.

The report is assessed using analyses such as SWOT analysis, Porters Analysis, predictive analysis, mechanistic analysis, and other essential analyses which are crucial to a good market research report. The report is perfectly suitable for all kinds of work approaches and is customizable to ensure maximum efficiency in the workflow.

Active Pharmaceutical Ingredients (API) Market Type Coverage: VitaminAntibioticsAntipyretic & AnalgesicHormoneAmino AcidNervus CentralisOthers

Active Pharmaceutical Ingredients (API) Market Application Coverage: HospitalClinicOthers

Market Segment by Regions and Nations included:

North America Country (United States, Canada)South AmericaAsia Country (China, Japan, India, Korea)Europe Country (Germany, UK, France, Italy)Other Country (Middle East, Africa, GCC)

Competitive Analysis:

The report has up to date data required to gain an edge over the different competitors in the Active Pharmaceutical Ingredients (API) market. The report has discussed in detail the mergers and acquisitions currently in place in the Active Pharmaceutical Ingredients (API) market landscape. The report illustrates an extensive account of the competitive landscape of the global market. The report will help our clients to navigate and emerge among the frontrunners of the market and for the current key players they will be able to sustain their lead in the market for a longer duration through the use of this report.

Get the discounted price for this report @https://www.reportsintellect.com/discount-request/1303972?RINT

About Us:

Reports Intellect is your one-stop solution for everything related to market research and market intelligence. We understand the importance of market intelligence and its need in todays competitive world.

Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you.So whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

Contact Us:

sales@reportsintellect.com Phone No: + 1-706-996-2486US Address: 225 Peachtree Street NE,Suite 400,Atlanta, GA 30303

Read more:
Active Pharmaceutical Ingredients (API) Market : Industry Analysis, Growth rate, and Future Forecast 2020-2026 - Stock Market Vista

Comments Closed|

Breast Reconstruction Surgery: Options, Benefits and Barriers – Michigan Medicine

October 20th, 2020

A breast cancer diagnosis rearranges priorities quickly for a woman. Along with possible treatments, such as hormone therapy, chemotherapy and radiation, most women also undergo surgical treatment which could include lumpectomy or mastectomy.

Once a successful course of treatment that includes a mastectomy ends, then what? For some women, part of recovery includes restoring a part of themselves that was removed.

Despite demonstrated psychosocial benefits breast reconstruction surgery can provide, some women either arent aware of all of the options available to them, or that they are candidates for reconstruction at all.

Jessica Hsu, M.D., Ph.D., a plastic surgeon at Michigan Medicine, says awareness is critical for women to make informed choices about how to proceed after cancer treatment.

Its a very personal decision. The important thing is to just have a conversation about all of the options, Hsu says.

Michigan Medicine has an integrated breast care clinic, and every woman diagnosed with breast cancer is offered a plastic surgery consultation. Once a patient decides to pursue breast reconstruction after total mastectomy, theyll likely be offered one of two main procedures offered at the clinic: Implant-based breast reconstruction or natural (also called autologous) tissue breast reconstruction.

Implant-based breast reconstruction uses implants that contain either silicone or saline, has a shorter recovery period and is the more common of the two procedures. Complications with the implants can arise, however, particularly in the case of women requiring radiation as part of their cancer treatment.

Natural tissue breast reconstruction involves moving tissue from another part of the bodymost often the patients abdomenand using that tissue flap to reconstruct a breast mound. Its a procedure that Paige Myers, M.D., a plastic surgeon at Michigan Medicine, specializes in performing. Myers is trained in microvascular surgery, which is required to reconnect the blood supply from the donor tissue to the reconstruction site in some cases.

Breast reconstruction using natural tissue is generally a more involved surgery with a longer recovery time, with a higher immediate complication rate. The upside is that it offers women more natural looking breasts, with tissue that changes along with their bodies and fewer future surgeries over time.

The benefits of autologous breast reconstruction surgery in people who are candidates for both tend to be more longevity of the reconstruction. The patients require fewer revisions down the road. Its your own tissue, so it ages with you naturally, Myers says.

Of course, one option is to not have reconstruction surgery to recreate breast mounds. As with all of the options, its a personal choice, and another one for women to consider.

Theres been a lot written on the flat and fabulous crowd and thats a form of breast reconstruction, Hsu says. They often still do have cosmetic concerns about their skin and we get involved in those cases.

Some women may not be interested in more surgery after undergoing a mastectomy. Hsu sees reconstruction as part of the treatment and recovery process, and points to the confidence women gain after reconstruction.

A lot of people think that the purpose of surgery is to restore function only, and they forget the other part, which is form, Hsu says. To help a woman have symmetric breasts after breast cancer surgery so they feel good in their clothing or in a swimsuit, and feel more like a woman with breast mounds, is really importantand really important to me.

Myers has seen examples of the powerful effects that breast reconstruction can have on a womans mental wellbeing. A happy patient once shared a photo of her son trying to breastfeed from a reconstructed breast after her surgery. To both mother and son, things seemed familiar in a way that was comforting.

According to Myers, so much of the breast cancer journey involves loss of control, and empowering women to determine what their bodies look like after mastectomy is another benefit.

Cancer diagnosis, therapy and everything that ensues takes so much away from patients, Myers says. To be in control of their own course of care, and what they feel is best for them, is another huge benefit.

Many barriers keep women from seeking a consultation or pursuing breast reconstruction surgery. Information overload is an issue for women who are already receiving a breast cancer diagnosis and the ensuing treatment.

Hsus typical consultations last about an hour. Women leave armed with pamphlets and are followed up closely to see if they have additional questions. Its a thorough process, but Hsu thinks theres room to improve the way information is delivered.

Our patients range from younger than 20 to people in their 70s and 80s, so its important to have resources that work for different age groups and different levels of technical comfort, Hsu says. There is an active effort at Michigan Medicine, led by Edwin Wilkins, M.D., to improve patient education resources and decision aids for breast reconstruction.

Myers understands that reconstruction takes a mental back seat to treatment.

When first faced with a cancer diagnosis, women are flooded with emotions and an onslaught of information, Myers says. Survival is the main thing on their minds, and that should be their priority. They receive all this information and then it seems reconstruction is put on the back burner.

The way the University of Michigan Rogel Cancer Centers multidisciplinary Breast Care Center brings the various treatment teams together helps to keep the options more top of mind for patients. According to Myers, not every health care setting has an integrated approach or structure.

Sometimes patients have trouble simply finding a clinic that can perform the surgeries. In some cases, a provider may not be able to offer an option that works and may not refer women elsewhere.

Women may not have access to a microsurgeon, geographically or otherwise, to perform the autologous reconstruction and, therefore, this can be a huge barrier for patients who arent candidates for implant-based reconstruction, Myers says.

The expense of breast reconstruction surgery may also deter women, especially if they dont think the results will be worth it. Hsu says its important to note that most group insurance providers that cover mastectomies are also required to cover breast reconstruction surgery, and that the coverage is more comprehensive than women might assume.

Coverage includes revision on the other side to achieve symmetry, Hsu says. Patients who are undergoing mastectomy on one side worry they wont be able to match the other side that didnt have cancer so they sometimes dont pursue it.

Hsu stresses that she and the rest of the team are eager to help women navigate questions and barriers, and to walk them through the options so that they ultimately make the decision thats right for them.

If you have questions, Im here, Hsu says. If you want to meet in five years, Im here. If you dont want to do it, thats your choice, and thats fine, too.

Read this article:
Breast Reconstruction Surgery: Options, Benefits and Barriers - Michigan Medicine

Comments Closed|

Reduce the risk of breast cancer | News, Sports, Jobs – Maui News

October 20th, 2020

This is National Breast Cancer Awareness Month. Maintaining that focus is important since breast cancer is the most common cancer in women worldwide, regardless of race, contributing more than 25 percent of new cancer cases.

Although more women are surviving, breast cancer has been on the rise for several years, and theres no simple answer as to why. Breast cancer is a complicated disease with a variety of different causes, and many aspects of our lives swing our risk in one direction or another. While some of these are out of our hands, others can be controlled, which is why eating healthy and exercising can help reduce risk.

As to what to drink, water is best, and coffee and tea are also useful because they contain antioxidants that can reduce your risk of cancer. You should eat a diet rich in vegetables and fruits. Foods to stay away from include grilled and red meat and processed foods. Eat them only occasionally.

If theres a history of breast cancer in your family, your risks are higher, and you should be informed on how to reduce it. A good place to start is the Mayo Clinic. Visit mayoclinic.org and search for reduce breast cancer risk for dozens of articles on that subject.

Youll learn what you likely already know: limit alcohol, dont smoke, control your weight, be physically active, breast-feed and limit hormone therapy. Be vigilant about breast cancer detection. If you notice any changes in your breasts, such as a new lump or skin changes, consult your doctor. Also, ask your doctor when to begin mammograms and other screenings based on your personal history, the clinic advises.

In addition to decreasing your risk of breast cancer, a healthy diet also staves off diabetes, heart disease and stroke. Says the clinic, Women who eat a Mediterranean diet supplemented with extra-virgin olive oil and mixed nuts might have a reduced risk of breast cancer. The Mediterranean diet focuses on mostly plant-based foods, such as fruits and vegetables, whole grains, legumes and nuts. People who follow the diet choose healthy fats, such as olive oil, over butter and eat fish instead of red meat.

To learn more about other ways you can help fight breast cancer, visit komeneasttennessee.org.

* Guest editorial from The Kingsport Times-News in Kingsport, Tenn.

Today's breaking news and more in your inbox

The confusion surrounding this weeks reopening to tourism reminded us of a spaceship plunging through Earths ...

Next year will bring higher prices at the post office. Anyone who didnt see this coming hasnt been paying ...

There is no excuse for a Louisiana State Police trooper to use foul language in the course of doing or discussing ...

What goes around comes around.You reap what you sow.Actions dictate consequences.Chickens come home to ...

The process was broken from the beginning, on March 12, when a judge in Kentuckys Jefferson County signed off on ...

This is Fire Prevention Week and a good time to take inventory. Families need to know what to do if a fire breaks ...

Continue reading here:
Reduce the risk of breast cancer | News, Sports, Jobs - Maui News

Comments Closed|

15 Greatest Methods to Enhance Your Libido, In response to Docs – KYR News

October 20th, 2020

Intercourse is without doubt one of the easiest issues on the planet, and probably the most sophisticated. In case your libido is flagging, it isnt as straightforward as flipping a swap again to on. Libido is pushed by plenty of components, says Michael Ingber, MD, a specialist in feminine pelvic medication and urology based mostly in Denville, New Jersey. The sexual response cycle requires a whole lot of issues to occur. That course of might be affected by food plan, way of life, stress and hormone rangessimply to call a couple of variables. In case your want is derailed and also you need to get again on observe, here is the place docs say you need to begin. Learn on to study the most effective methods to extend libido, and to make sure your well being and the well being of others, do not miss these Sure Signs Youve Already Had Coronavirus.

1

Strolling or performing some sort of motion train every day reduces irritation, boosts intercourse drive and improves the blood movement to the intercourse organs, says Yeral Patel, MD, a purposeful medication doctor in Newport Seaside, California. This small adjustment could make a giant distinction.

Train can also improve the output of pure endorphins, making one really feel calm and horny, says Felice Gersh, MD, an OB/GYN and founder/director of the Integrative Medical Group in Irvine, California. After all, train helps each women and men change into buffand a physique you are feeling horny in goes an extended technique to growing the will for intercourse.

The Rx: Goal to get 30 minutes of train most days of the week, together with at the least two periods of power coaching weekly.

2

Chocolate incorporates many mood-enhancing and energy-producing chemical compounds, so it is no surprise we affiliate chocolate with friskiness, happiness and sexual cravings and satisfaction, says Anna Cabeca, DO, an OB-GYN and anti-aging doctor and writer of The Hormone Repair. It incorporates theobromine (a temper elevator), caffeine and sugar (a temper elevator and vitality booster) and the endorphin Phenylethylamine (PEA) which produces an vitality enhance.

Story continues

The Rx: Attempt a couple of squares (a 1 to 2 oz. serving) of darkish chocolate for dessert.

Three

Persistent stress retains this intercourse drive low, says Myles Spar, MD, MPH, an inner medication doctor and writer of Optimum Maless Well being. The easiest way to repair that is to learn to handle stress in order that the physique just isnt all the time in fight-or-flight mode, feeling like you might be below assault on a regular basis.

The Rx: Day by day habits like journaling, breathwork, mindfulness observe, meditation, mild yoga and even prayer have been proven to considerably decrease the sympathetic nervous system overdrive state and create a way of rest, says Spar. Then intercourse drive will increase, as a result of the mind senses that it is time for copy. It is all evolutionary.

four

Sleep is necessary. There have been a number of research that present a scarcity of sleep negatively impacts intercourse drive. So ensure youre well-rested otherwise you will not be up for the duty, says Ingber.

The Rx: Specialists advocate seven to 9 hours of sleep nightly for the optimum efficiency of your coronary heart, mind, metabolismand intercourse drive.

5

Chubby and overweight sufferers have elevated irritation which causes hormone imbalance and thus, could cause low libido and low intercourse drive, says Patel.

The Rx: Keep in a wholesome weight vary with common train and a balanced food plan.

6

Most processed meals include hormone-altering chemical compounds that may wreak havoc on (amongst different issues) intercourse drive, says Patel.

The Rx: As an alternative of packaged meals, Patel recommends consuming beets and spinach, that are excessive in pure nitrates that assist improve blood movement to the intercourse organs; lycopene-rich meals comparable to citrus and tomatoes, which additionally improve blood movement; and meals excessive in flavonoids, comparable to darkish chocolate, blueberries, strawberries and inexperienced tea. These assist strengthen and heal blood vessels.

RELATED: Im a Doctor and This Vitamin May Reduce Your COVID Risk

7

Oysters have been acknowledged for hundreds of years as a traditional aphrodisiac, says Cabeca. Oysters include dopamine, a hormone recognized to extend libido. Oysters and most shellfish additionally include arginine, an amino acid that the physique makes use of to make nitric oxide. Nitric oxide will loosen up and develop your blood vessels, very similar to the erectile dysfunction drug Viagra, thereby growing libido. Avocados are excessive in vitamin B6, which helps improve hormone manufacturing and enhance libido for each sexes, she provides.

The Rx: Indulge within the occasional oyster dinner. Avocados might be part of your every day menuon salads, in smoothies, or as a facet dish for lean protein.

eight

Toxins are one other stressor on our our bodies that may affect hormone manufacturing and may bind to hormone receptors, says Stephanie Gray, DNP, MS, founding father of the Integrative Well being and Hormone Clinic in Hiawatha, Iowa. Work to take away poisonous chemical compounds from your own home and out of your private care merchandise.

The Rx: One of many frequent toxins is plastics. Plastic usually incorporates bisphenol A (BPA), an endocrine disruptor that may have damaging results on our reproductive organs and hormones, particularly the breasts in females and prostate in males, says Grey. Some private care merchandise additionally include parabens and phthalates (extra endocrine disruptors), so learn the labels and keep away from merchandise that merely listing added perfume, since this catch-all time period typically means hidden phthalates.

9

Too usually sufferers see me stating, My physician already checked my hormones and advised me they have been regular when that is not actually the case, says Grey. Possibly that they had an FSH (menopause) marker checked however did not even have intercourse hormone ranges like estradiol, estrone, progesterone, and testosterone checked.

The Rx: Past having the degrees checked, discover a hormone specialist who can correctly interpret your hormone ranges and formulate a recreation plan to enhance them, says Grey. Simply because ranges register within the regular vary does not imply theyre optimum.

10

Similar to males, testosterone is the principle steroid hormone which causes libido to extend in girls. So consider it or not, we frequently give this to girls whove a low libido, says Ingber. Additionally, hormones like dopamine, oxytocin, and serotonin play a task.

The Rx: Sure prescription drugs, comparable to Addyi and Vyleesi, are prescribed to deal with decreased sexual want in girls, says Ingber. If low testosterone is a reason for a persons low intercourse drive, testosterone substitute remedy (TRT) is on the market.

11

Ristela (Bonafide) is a brand new pure remedy which is a plant-based mix of french maritime pine bark extract, antioxidants and naturally occurring amino acids. It was proven to extend bodily arousal by 75% after solely two months of taking it, says Ingber.

The Rx: See your healthcare supplier about whether or not a nutraceutical is an efficient choice for you.

12

Im usually requested about low libido and what choices can be found for ladies whore experiencing a low sexual want with their accomplice, says Lyndsey Harper, MD, founding father of Rosy, an app for ladies with decreased sexual want. My reply is all the time the identical regaining your sexual want is like setting a brand new aim. It requires a dedication and dedication to making an attempt one thing new that could be out of your consolation zone and sticking with it till you attain your aim.

The Rx: One of many evidence-based interventions I like to recommend is studying a romantic or horny brief story earlier than you propose on having intercourse, says Harper. Studying an attractive story can rev up sexual vitality and open up the room for pleasure and pleasure. After you have a optimistic and pleasurable sexual expertise, this in and of itself will assist you regain intimacy and create a bodily connection and appreciation together with your accomplice.

13

A food plan excessive in inexperienced leafy greens, beets, and citrus fruits and melons is an effective way to boost the manufacturing of nitric oxide, the gasoline signaling agent that causes vascular engorgement of the penis and of the feminine labia minora and clitoris, says Gersh.

The Rx: Are you getting sufficient? The Dietary Pointers for Individuals recommends consuming 2 cups of fruits and a pair of cups of greens each day. (However extra would not damage.)

14

Antioxidants can vastly assist within the enjoyment of intercourse by growing genital blood movement, reducing body-wide irritation, and enhancing ranges of intercourse hormones, says Gersh. Some dietary supplements can even elevate ranges of nitric oxide, offering its precursor, like beet powder and Vitamin C.

The Rx: For dietary supplements, I might counsel maca as an total finest aphrodisiac, says Gersh. However do not forget a multivitamin, vitamin D and Okay, zinc, magnesium, omega-Three, probiotics, B12, folate and a B advanced.

15

If there are relationship issues, they should be addressed very first thing, says Gersh. Relationship discord causes large stress, which lowers libido. Stress of every type should be dealt with, and most notably when the stress entails that couple.

The Rx: In case you have conflicts to work out together with your accomplice, counseling and stress-reduction workouts are sensible methods. Attempt meditation or guided imagery to enhance tolerance of one other and of oneself, says Gersh. Have a good time the little beauties of life, and attempt to maintain the bigger points emotionally managed.

As for your self: To get by way of this pandemic at your healthiest, do not miss these 35 Places Youre Most Likely to Catch COVID.

See the original post here:
15 Greatest Methods to Enhance Your Libido, In response to Docs - KYR News

Comments Closed|

Young women may be likelier to die after heart attacks than men – Live Science

October 20th, 2020

Younger women may be more likely to die in the decade following a heart attack than men of the same age, a new study suggests.

In general, women under age 50 experience fewer heart attacks than men in the same age range. The new study, published Oct. 13 in the European Heart Journal, also reflects this trend; of 2,100 heart attack patients treated at the Brigham and Women's Hospital and Massachusetts General Hospital in Boston between 2000 and 2016, only about 400 were women. The average age of all the patients in the study was 44 years old.

But over the long-term, these young women were more likely to die than young men. The study authors followed the patients for a median of 11 years, and found that women were 1.6 times more likely to die from any cause than men during that time.

Related: 9 new ways to keep your heart healthy

"Notably, the differences in mortality in our study were primarily driven by non-cardiovascular death," meaning deaths not caused by a heart condition, study author Dr. Ersilia DeFilippis, a cardiology fellow at New York Presbyterian-Columbia University Irving Medical Center, told Live Science in an email. Examples of these non-cardiovascular causes of death included cancer and sepsis, a kind of overblown immune response to an infection.

Unfortunately, "there were no clear explanations as to why women had lower survival," DeFilippis noted, though the study revealed a number of factors that may be at play.

"The risk factors for disease of other organs overlap with risk factors for heart disease," Dr. Marysia Tweet, an assistant professor in Cardiovascular Medicine at the Mayo Clinic, who was not involved in the study, told Live Science in an email. "A heart attack and the ramifications of a heart attack may affect the health of other organs. Long-term mortality is likely due to a combination of multiple factors."

For instance, women in the study had higher rates of diabetes than the men, as well as higher rates of diseases such rheumatoid arthritis , where joint pain and inflammation are often triggered by an immune system attack. This persistent inflammation may drive the formation of fatty plaques in blood vessels, which can block arteries and lead to a heart attack, according to a 2012 report in the journal Arteriosclerosis, Thrombosis, and Vascular Biology. That same inflammation may also affect how patients recover.

In addition, the women showed higher rates of depression than men in the study. "Depression impacts adherence to healthy lifestyle recommendations and medications," which could impact women's long-term survival after a heart attack, Tweet wrote in a commentary also published in the European Heart Journal about the research. But it's also possible that the physiological changes that coincide with depression independently worsen outcomes; for instance, elevated levels of stress hormones and inflammatory molecules called cytokines could worsen a patient's prognosis, she wrote.

In general, women are about twice as likely as men to experience stress-induced reduction in blood flow to organs after a heart attack, according to a 2018 report published in the journal Circulation.

Related: Beyond vegetables and exercise: 5 surprising ways to be heart healthy

Beyond these risk factors, women also received different care from men when being treated for their heart attacks.

Women in the study were less likely than men to undergo coronary angiography, an exam in which dye is injected into the blood vessels so doctors can view those vessels and possible blockages on X-ray. They were also less likely to receive coronary revascularization, in which blood flow is restored through surgery or placement of a stent into the obstructed artery. When discharged from the hospital, women were less likely to be given medications like aspirin, beta-blockers, ACE inhibitors and statins, which are often prescribed after a heart attack to protect the organ from further damage.

These differences in medical care may reflect "persistent sex or gender disparities in clinical care and decision-making," or they may reflect clinical differences in how the men and women's heart attacks unfolded, Tweet wrote. For example, more women than men developed a spontaneous tear in an artery in the heart, which would deter doctors from performing an invasive procedure like coronary revascularization.

Women were also less likely to have severe blockages in their coronary arteries as compared with men, which would also reduce the need for coronary revascularization, Dr. Ron Blankstein, a professor of medicine at Harvard Medical School and a preventive cardiologist at Brigham and Women's Hospital, wrote in a statement.

Related: 7 foods your heart will hate

Socioeconomic status may be another critical factor in women's long-term survival rates, the authors wrote. "In our study, we found that women had lower median incomes than men and were more likely to have public insurance," DeFilippis said. "Therefore, there are likely differences in access to care which are playing a role."

Further studies will be needed to tease out how these factors affect women's long-term survival after a heart attack, the authors noted. In the meantime, cardiologists "need to educate women regarding the risks of cardiovascular disease and potential worrisome symptoms," DeFilippis said. In the study, chest pain was the most commonly reported symptom among both men and women, but a higher proportion of women reported symptoms like shortness of breath, heart palpitations and fatigue.

Doctors can improve women's care by recruiting more women into clinical trials, actively including sex-based data in studies of heart attacks and better addressing sex-specific risk factors when educating patients, Tweet wrote in her commentary. For instance, gestational diabetes and preeclampsia severely high blood pressure during pregnancy can place women at higher risk for heart attacks, she wrote. Ovary removal has also been associated with a higher risk of heart attacks, potentially because ovaries produce the sex hormone estrogen, which is thought to protect against heart disease, according to Harvard Health.

Furthermore, some research suggests that women face greater cardiovascular risks from smoking than men do; all these risk factors warrant further study, especially in terms of whether the risk they present outmatches the protective power of estrogen and leaves women more prone to heart attacks, the authors wrote.

Originally published on Live Science.

See the article here:
Young women may be likelier to die after heart attacks than men - Live Science

Comments Closed|

Skateboarding the latest accomplishment for Westerville boy with rare genetic disorder – The Columbus Dispatch

October 20th, 2020

Ken Gordon|The Columbus Dispatch

Watching his son Sora crouched low on a skateboard recently, gliding smoothly down a ramp at Adventure Park in Powell, Tristan Chamberlain thought of all the things that doctors had said Sora would never do.

Born in 2015 with Prader-Willi Syndrome, a rare genetic disorder, the outlook for Sora was uncertain. The syndrome affects about 1 in 15,000 children andtypically leaves themwith low muscle tone, abnormal growthand intellectual disabilities, among other issues.

They told us there was a good chance he would have to use a walker for the rest of his life, Chamberlain said. At 3, he was walking on his own. Then they said, `Well, hes walking now, but he wont be able to run and play like normal kids can do.

So then we got him running around, and they said he probably wont be able to do other things like jumping.

He pulled out his phone and showed off a picture of Sora, now 5,jumping off a large climbing rock at a different park.

A skateboarder in his youth he calls Sora"little dude" and uses the term "gnarly" often Chamberlain, 39, introduced Sora to the sport as a way to keep up his son's muscle tone and balance during the COVID-19 pandemic, when hisphysical therapy sessions were temporarily halted.

Chamberlain said skateboarding has helped Sora both physically and socially. And the skate community, he said, has been welcoming.

"His reaction time is a lot better, he can anticipate things," he said. "And the skills he has developed here have translated into other things, like his running is so much better now."

As for the doctors' gloomy predictions, he said he understands why doctors are hesitant to be overly optimistic, not wanting to provide false hope. But he along with his wife, Tomomi Tanaka never bought into the idea that Soras potential was limited, even after more obstacles were added to his path. He was diagnosed with cerebral palsy 18 months ago and also is on the autism spectrum.

Every new parent has this fantasy of what its going to be like to have a child, and sometimes life punches you in the face, TristanChamberlain said. But having a special-needs child has been the most rewarding thing in my entire lifebecause it taught me to quit worrying about things I cant control.

I cant change the fact that my son has a genetic disorder, but I can change myself and be the best dad possible.

For the Chamberlains, that has meant being aggressive advocates for Sora. That philosophy included approving a regimen of human growth hormone for their son, starting at 6 months of age.

The hormone, approved as a treatment for Prader-Willi in 2000, helps build muscle tone and possibly can help improve cognitive function, as well, according to Dr. Kathryn Obrynba, an endocrinologist at Nationwide Childrens Hospital and medical director of the hospitals Prader-Willi Syndrome Clinic.

Prader-Willi patients have a malfunctioning hypothalamus, the part of the brain that regulates essential functions such as hunger, body temperature and pain.

The natural course of this disease is changing every day because parents like Soras have advocated for change and been onboard with therapies like early growth hormone, Obrynba said. What may have been expected of patients 10 years ago is different from what we anticipate or expect now.

The Chamberlains have had Sora in physical therapy, occupational therapy and speech therapy for years. Not long after the physical therapy stopped this spring, Tristan Chamberlain was cleaning out the garage one day when Sora found his old skateboard.

He picked it up and said, `I want to ride it, Chamberlain said.And I thought, `Why the heck not?

The two started in April in the driveway of their Westerville home, learning to balance and stay on the board. By June, Chamberlain began taking Sora to a skatepark.

His wife, though, does not come and watch. Its a 'mom thing. Chamberlain's mother, Stephanie Chamberlain, said she can relate.

I remember the first time I watched Tristan drop in (to a steep ramp), I thought I was going to throw up, she said while watching her son and grandson at Adventure Park recently during a visit from her home in North Carolina.

All padded up and helmeted, Sora skates confidently, though on this day the park was crowded, and Chamberlainseveral times had to spring into action and guide Sora out of another skaters path. After seven runs, Sora got tired and a little cranky. It was time to head home, where he could play with his 3-year-old younger brother, Kai.

Chamberlainsaid Kai, a typically developing child, has been good for Sora, as has been his pre-kindergarten experience at the Westerville school districts Early Learning Center. The Chamberlains moved from German Village two years ago just so Sora could attend.

There, he and other special-needs kids are in a classroom with typical kids. The goal is to normalize special needs, and also perhaps for the typically developing kids to push Sora to try harder.

It is a phenomenal environment, Chamberlain said.

Obrynba said she wasnt aware that Sora wasskateboarding, but she isnt surprised.

Thats awesome, she said. Tristan and Tomomi support Sora amazingly. Im so impressed with what they do.

The Chamberlains also are involved in fundraising campaigns for Prader-Willi Syndrome. Tristan Chamberlain is particularly proud of aninitiative he and a friend are planning, a line of skateboards that will be sold to benefit research.

They are imprinted with a phrase that he says is inspired by the memories of being told what Sora would never do:

Yes, I Will.

kgordon@dispatch.com

@kgdispatch

See the article here:
Skateboarding the latest accomplishment for Westerville boy with rare genetic disorder - The Columbus Dispatch

Comments Closed|

Impact Of Covid-19 On Blood Testing Market Is To Witness Significant Growth Between 2020-2027 With Leading Players Abbott Laboratories, Bio-Rad…

October 20th, 2020

A new research study has been presented by Dataintelo.com offering a comprehensive analysis on the Global Blood Testing Market where user can benefit from the complete market research report with all the required useful information about this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report discusses all major market aspects with expert opinion on current market status along with historic data. This market report is a detailed study on the growth, investment opportunities, market statistics, growing competition analysis, major key players, industry facts, important figures, sales, prices, revenues, gross margins, market shares, business strategies, top regions, demand, and developments.

The Blood Testing Market report provides a detailed analysis of the global market size, regional and country-level market size, segment growth, market share, competitive landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunity analysis, strategic market growth analysis, product launches, and technological innovations.

Get a Free Sample Copy of the Blood Testing Market Report with Latest Industry Trends @ https://dataintelo.com/request-sample/?reportId=79004

Major Players Covered in this Report are: Abbott LaboratoriesBio-Rad LaboratoriesF. Hoffmann La RocheSiemens Healthineers

Global Blood Testing Market SegmentationThis market has been divided into Types, Applications, and Regions. The growth of each segment provides an accurate calculation and forecast of sales by Types and Applications, in terms of volume and value for the period between 2020 and 2026. This analysis can help you expand your business by targeting qualified niche markets. Market share data is available on the global and regional level. Regions covered in the report are North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Research analysts understand the competitive strengths and provide competitive analysis for each competitor separately.

By Types:GlucoseLipidBUNA1CCRPVitamin DALTASTThyroid Stimulating Hormone

By Applications:HospitalsClinic and Diagnostic CentersOthers

To get Incredible Discounts on this Premium Report, Click Here @ https://dataintelo.com/ask-for-discount/?reportId=79004

Global Blood Testing Market Regions and Countries Level AnalysisRegional analysis is a highly comprehensive part of this report. This segmentation sheds light on the sales of the Blood Testing on regional- and country-level. This data provides a detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market.

The report offers an in-depth assessment of the growth and other aspects of the market in key countries including the US, Canada, Mexico, Germany, France, the UK, Russia, Italy, China, Japan, South Korea, India, Australia, Brazil, and Saudi Arabia. The competitive landscape chapter of the global market report provides key information about market players such as company overview, total revenue (financials), market potential, global presence, Blood Testing sales and revenue generated, market share, prices, production sites and facilities, products offered, and strategies adopted. This study provides Blood Testing sales, revenue, and market share for each player covered in this report for a period between 2016 and 2020.

Make an Inquiry of this Report @ https://dataintelo.com/enquiry-before-buying/?reportId=79004

Why Choose Us:

Table of Contents1. Executive Summary2. Assumptions and Acronyms Used3. Research Methodology4. Market Overview5. Global Market Analysis and Forecast, by Types6. Global Market Analysis and Forecast, by Applications7. Global Market Analysis and Forecast, by Regions8. North America Market Analysis and Forecast9. Latin America Market Analysis and Forecast10. Europe Market Analysis and Forecast11. Asia Pacific Market Analysis and Forecast12. Middle East & Africa Market Analysis and Forecast13. Competition Landscape

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, US.Phone No: US: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://dataintelo.com

The rest is here:
Impact Of Covid-19 On Blood Testing Market Is To Witness Significant Growth Between 2020-2027 With Leading Players Abbott Laboratories, Bio-Rad...

Comments Closed|

There is a disconnect between the mind and body – A transgender woman’s journey exposes her to the difficulties experienced by her community – News24

October 13th, 2020

A young Phumelela in Grade 1

Supplied: Phumelela Nkomozake

"My journey started, as [far back] as I could remember, being a young child growing up and always noticing that there is something particular about you or that you really do not find yourself comfortable in your own body.It is feeling in a particular way that there is a disconnect between your mind and your body."

These are the words of 24-year-old Phumelela Nkomazake, a transgender woman from the Eastern Cape whose personal journey towards affirming her gender led her to discover that the journey was more than just about her, and that it was one that the transgender community experiences as a whole.

Subscribe to News24 and get access to our exclusive journalism and features today.

Read the rest here:
There is a disconnect between the mind and body - A transgender woman's journey exposes her to the difficulties experienced by her community - News24

Comments Closed|

Should you freeze your eggs? IVF websites don’t crack the surface – Sydney Morning Herald

October 13th, 2020

IVF clinics vied for patients in this highly competitive environment knowing women considering freezing their eggs scoured clinic websites and social media for guidance, Dr Beilby said.

"There's a lot of money involved in fertility preserving technology, and it's great to know this technology exists to meet the demand," she said.

But clinics had an obligation to provide clear, accurate information alongside their marketing material about what egg freezing entails, the chance of success, and the cost. "That's what we're not seeing," Dr Beilby said.

None of Australia's 21 most prominent fertility clinic websites specified whether the egg-freezing success rates they quoted were based on patients using their own eggs or donated eggs from cohorts of 20-something women.

Only half provided success rates based on a woman's age and fewer than one-third included the cost of the procedure, according to the analysis published in the Australian and New Zealand Journal of Obstetrics and Gynaecology.

One in three clinic websites published a percentage figure for the chance of getting pregnant after egg-freezing, but only one in 10 published the chance of having a baby.

Overall, the researchers rated 43 per cent of the clinics as "poor" and 57 per cent as "moderate" on an American matrix designed specifically to assess the quality of information on egg freezing.

Co-author Dr Karin Hammarberg said women need to be properly informed of these high costs, potential health risks and chances of having a baby before they decide to undergo egg freezing.

The chance of having a baby from frozen eggs depends on two numbers: the age of a woman when her eggs are frozen, and the number of eggs she freezes, Dr Hammarberg said.

Loading

The quality of a woman's eggs declines the older she gets. The older the woman, the more eggs she'll need to freeze to have a reasonable chance of having a baby.

For a women under 30, the chance of taking home a baby per initiated IVF cycle if she uses her own eggs is 19.7 per cent, the latest official IVF data from the Australian and New Zealand Assisted Reproduction Database shows.

FFor women aged 30 to 34, it is 17.5per cent, dropping to 12.1 per cent for 35- to 39-year-olds, 4.6 per cent for 40- to 44-year-olds and 0.4 per cent for women 45 and over.

Freezing 10 eggs at 35 or younger gives a woman a 69 per cent chance of having a live birth, dropping to 50 per cent for 37-year-olds and 30 per cent for 40-year-olds.

The number of stimulation cycles needed to retrieve enough eggs increases with age. Most women over 35 will need more than one egg retrieval to collect enough eggs to have a reasonable chance of success.

More than half of the women who freeze their eggs when they are in their mid to late 30s will need at least two hormone stimulations to get the number of eggs that gives them an 80 percent chance of having a baby when they use their eggs. Almost all women aged 40 or more will need at least four hormone stimulations for the same chance.

There is also a third number to consider: cost. The egg-freezing process can cost $7000 to $10,000 per egg retrieval plus the additional cost of storing the eggs (approximately $200 to $500 a year).

"Something that may not be obvious is that in order to have a good reasonable chance of having a baby you might need to spend $30,000," Dr Beilby said.

The egg retrieval process also involves health risks, such as ovarian hyper-stimulation syndrome (OHSS), which is associated with the hormone injections required as part of the procedure.

Dr Beilby hoped clinics would use the audit to develop a checklist of information to include on their websites, and where possible publish clinic-specific success rates.

"There is a lot of hope tied up in this, and we need to err on the side of caution to align women's expectations with reality," Dr Beilby said.

Professor Luk Rombauts, President of the Fertility Society of Australia, said a consultation with a fertility specialist - not the internet - was the appropriate setting for a woman to be given the information she needed to make an informed decision about egg freezing.

"Just because it's not on the website doesn't mean patients won't get that information," Professor Rombauts said. "They will get it from their doctor, which is exactly where the information should be coming from. Most importantly, we will take into account a patient's personal circumstances."

Loading

Professor Rombauts said the fertility industry had done exceptionally well when it came to transparency in advertising compared to other medical specialities.

It was impossible - particularly for smaller clinics - to provide meaningful success rates when only a very small proportion of women have returned to use their frozen eggs.

"A lot of women who freeze their eggs fortunately never have to use them because they do find a partner," he said. "That doesnt mean we couldn't improve the reporting on our websites."

In Australia, the FSA's Reproductive Technology Accreditation Committee sets standards for ART clinics through an audited Code of Practice, which states their websites "must include but not be limited to: processes, costs, risks and outcomes" but does not specify a minimum level of detail.

"This paper could give [clinics] another useful tool when they're considering what information they could include on their websites," Professor Rombauts said.

Kate Aubusson is Health Editor of The Sydney Morning Herald.

Read this article:
Should you freeze your eggs? IVF websites don't crack the surface - Sydney Morning Herald

Comments Closed|

Do You Have Dryness, Vaginal Atrophy or Vaginitis? – Bioidentical Hormone Health

October 13th, 2020

At menopause as hormone levels decline, women start noticing signs of dryness or tightness and sex may become uncomfortable

There are several reasons for this, and a number of conditions that can arise at this time may need to be investigated.

Dealing with dryness

This is most common at menopause and related to the declining oestrogen levels that occur at this time.

This is not serious physically, though can certainly be distressing, and there are a number of lubricants available.

If you have mild to moderate vaginitis, using a lubricant can help relieve pain and discomfort while having sex but they provide short-term symptom relief and can improve vaginal dryness during sex, but theres no evidence to show theyre an effective long-term treatment.

Several types of lubricant are available some are water-based and some aresilicone-based. You may need to try a few before finding one thats suitable or your GP may wish to prescribe a localoestrogen cream, gel or pessary.

If you prefer a natural alternative then 20-1, which is a combination cream with the majority ingredient of progesterone with two natural oestrogens added, can help particularly if internal vaginal application is used.

Vaginitis

This is inflammation of the vagina that can cause itching, discomfort and discharge. Itcan be caused by any of the following infections or irritants:

thrush a common yeast infection that affects most women at some point

bacterial vaginosis a bacterial infection where the balance of bacteria inside the vagina is disrupted

trichomoniasis an STI (Sexually Transmitted Infection) caused by a tiny parasite

chemical irritation for example, from perfumed soap, bubble bath, or fabric conditioner, or from spermicide and somesanitary products

washing inside your vagina

chlamydia an STI caused by bacteria

gonorrhoea an STI caused by bacteria

genital herpes an STI caused by the herpes simplex virus.and symptoms include:

Symptoms can include the following

an abnormal vaginal discharge

vaginal irritation or itching

pain when peeing or having sex

light bleeding or spotting

a strong, unpleasant smell, particularly after sex, can be a sign of bacterial vaginosisor trichomoniasis, which can sometimes cause vaginitis.

Time to see your GP orgo to a sexual health clinicif you have any unusual vaginal symptoms, particularly if you have :

vaginal itching or an unpleasant smelling vaginal discharge

havent had a vaginal infection before

had vaginal infections before but now your symptoms are different

had a number of sexual partners, or you have a new sexual partner so you may have a sexually transmitted infection (STI)

finished a course of medication for vaginal thrush, but your symptoms are persisting

Theres no need to see your GP if youve been diagnosed with thrush in the past and your symptoms arethe same.If youre sure you have thrush and youve treated it successfully in the past with over-the-counter medication, you can treat it yourself again.

Treating vaginitis

Treatment for vaginitis depends on whats causing it.Yeast infections, such as vaginal thrush, are usually treated with antifungal medicines, and bacterial infections are usually treated with antibiotics.

Vaginal atrophy

This refers to thethinning of the lining of the vagina after the menopause and the resultingdryness, itching or discomfort (particularly during sex). It can also sometimes be caused by a decrease in oestrogen levels after the menopause.

Your GP may recommend using a local oestrogen and that is usually necessary with atrophy until the condition is more stable.

Unlike combined or other forms of HRT, thisonly restores oestrogen to your vagina rather than to your whole body, reducing the risk of side effects.

You can balance this additional oestrogen with bioidentical progesterone, and once the atrophy is under control you can use a combined bioidentical progesterone and oestrogen cream.

How to help yourself

There are number of self-help measures which can reduce the risk of these problems and help once they are diagnosed.

keep your genital area clean and drytake a warm bath rather than a hot one and useunperfumed soap to clean your genital area anddry yourself thoroughly

avoid douching (spraying water inside your vagina) it may make your vaginitis symptoms worse by removing the healthy bacteria that line the vagina and help keep it free from infection

do not use feminine hygiene products such as sprays, deodorants or powders

use pads rather than tampons if youre using intravaginal creams or pessaries to treat an infectiontampons may soak up the treatment meaning theres less available in the vagina

wear loose-fitting cotton underwearthis may be beneficial if you have external soreness, but it wont prevent you getting vaginitis in the future

Helpfulinformation:

Because women are often reluctant to talk about conditions like this, they do often suffer in silence but there really is no need as help is readily available.

Generally, maintaining good hormone balance with healthy levels of progesterone and oestrogen is a helpful measure too.

For any of these condition it is best topractice safe sex by usingcondoms to avoid getting or spreading sexually transmitted infections.

What Are the Symptoms of UTIs?

The rest is here:
Do You Have Dryness, Vaginal Atrophy or Vaginitis? - Bioidentical Hormone Health

Comments Closed|

The Fight for Reproductive Justice in a Post-Ginsburg World – The Intercept

October 13th, 2020

Oriaku Njoku was outside the U.S. Supreme Court alongside a crowd of activists and advocates for abortion rights as the nine jurists inside heard oral arguments in a case that, depending on its outcome, could destroy access to abortion in Louisiana.

It was a crisp morning in early March, mere days before the coronavirus pandemic would see the country all but completely locked down. Njoku, one of the founders of Access Reproductive Care-Southeast, a nonprofit that provides assistance to individuals seeking abortion care across six states in the Deep South, was rallying outside the court with her sister. There was so much energy, she recalled.

It was nearly four years to the day since the last time Njoku had been in front of the high court. That morning, in early 2016, the court was considering the constitutionality of a set of abortion restrictions in Texas that had shuttered half the states clinics. At the time, there were just eight justices on the bench; Antonin Scalia had died several weeks earlier. In the end, Anthony Kennedy joined the four more liberal justices, including Ruth Bader Ginsburg, to strike down the restrictions, which included a requirement that abortion providers have admitting privileges at a local hospital. The court found no evidence that this was necessary to ensure patient safety.

Now, Njoku was back in the same space rallying for the same cause: The restriction at issue in the Louisiana case was identical to the admitting privileges requirement the court had invalidated in Texas. It was a full-circle moment, where it was almost four years to the day; Im back here again, literally fighting for the same thing, she said. I was like, They have to uphold this precedent.

By then, Kennedy had left the bench and President Donald Trump had installed two new conservative justices, Neil Gorsuch and Brett Kavanaugh, who were appointed precisely because of their hostility to abortion. In the end, the court did strike down the Louisiana law, with Chief Justice John Roberts casting the deciding vote albeit with an opinion suggesting the court would be open to upholding additional restrictions in the future.

When the decision was announced, Njoku realized that it wasnt exactly a game-changing victory. Anti-abortion lawmakers have passed more than 450 abortion restrictions over the last decade, many of which still stand, making access to abortion difficult, if not nearly impossible, for millions of people. This is especially true for people of color, LGBTQ people, poorand low-income people, and people in rural areas, who are routinely hit hardest by restrictions on reproductive care, as well as broader inequalities within the health care system. These inequalities have been widely exposed not only by the pandemic, but also through a summer of civil rights protests that have thrown new light on the countrys continuing legacy of racial oppression.

Judge Amy Coney Barrett, President Donald Trumps nominee to the Supreme Court, at the U.S. Capitol on Oct. 1, 2020, in Washington, D.C.

Photo: Caroline Brehman- Pool/Getty Images

And with Ginsburgs death in September, the fight for reproductive justice faces new threats as Republicans scramble to fill her seat with appeals court jurist Amy Coney Barrett, who in 2006 signed on to a call for Roe v. Wade to be overturned, which described its legacy as barbaric. According to the Center for Reproductive Rights, if that were to happen, 24 states would prohibit abortion altogether.

If Barrett is seated, not only is the future of legal abortion in jeopardy, but also access to the larger health care system; the Supreme Court is slated to hear yet another challenge to the Affordable Care Act on November 10. Yes, this is a huge blow, but it doesnt stop the fact that we still have to do work on the ground, as grassroots organizations, as people who are directly impacted by whatever this administration has done or that prior administrations have done, Njoku said. We have to continue fighting until we get to that future of reproductive justice where were able to access whatever health care that we need without any bias or barrier.

WhileGinsburgs seat is still vacant, the Trump administration has already offered the eight-member court an opportunity to restrict abortion access amid the pandemic.

At issue is how medication abortion is provided to people seeking to terminate a pregnancy in its earliest stages. Available through 10 weeks gestation, medication abortion is a two-drug regimen that has been available in the U.S. for 20 years and used by more than 4 million people. Medication abortion accounts for 60 percent of all early terminations and nearly 40 percent of all abortions, according to the Guttmacher Institute.

It works like this: Patients first take mifepristone, a drug that blocks progesterone, a hormone needed to maintain pregnancy; 24 to 48 hours later, the patient takes a second drug, misoprostol, which creates contractions in the uterus that expel its contents. According to the U.S. Food and Drug Administration, medication abortion is very safe and serious complications are extremely rare. Importantly, medication abortion allows patients the ability to terminate a pregnancy in the privacy of their own home or wherever they choose to be.

Nonetheless, access to medication abortion has been restricted in ways that are medically unnecessary. The needless barriers amid a pandemic place individuals at greater risk of contracting Covid-19, according to a federal lawsuit the American Civil Liberties Union filed against the Trump administration in May on behalf of several doctors organizations and a leading reproductive justice group.

Even as state and federal health officials have implored people to avail themselves of telemedicine, abortion patients have been singled out for disparate treatment.

Medication abortion is constrained by what the FDA calls a Risk Evaluation and Mitigation Strategy, a drug safety program designed to control the administration of certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. Where medication abortion is concerned, the REMS has several elements that are onerous in normal times and two that are particularly problematic amid a pandemic: that patients must be handed mifepristone by a medical provider in a clinical setting and that the clinician must collect a physical signature from the patient at the time the drug is dispensed.

While in-person dispensing is required, patients are still in charge of administering the protocol themselves at a time and place of their choosing. And any complications that may arise such as excessive bleeding wouldnt occur until roughly two days later, after the patient ingests the second drug, misoprostol, which is not subject to the REMS. Of the 20,000 drugs regulated by the FDA, mifepristone is the only one that patients must receive in person at a hospital, clinic, or medical office, yet may self-administer unsupervised, reads the lawsuit.

So, even as state and federal health officials have implored people to avail themselves of telemedicine as much as possible, abortion patients have been singled out for disparate treatment, said Julia Kaye, a staff attorney with the ACLUs Reproductive Freedom Project. When youre forcing patients to make unnecessary, in-person trips to a health center during a pandemic, that imposes Covid-19 risks, and theres simply no justification for it, she said, particularly where the federal government has taken extraordinary action to suspend other kinds of in-person requirements. The government has even suspended in-person requirements for controlled substances, including opioids. And I think its important to note that the Covid-19 risks here are greatest for communities of color who make up a majority of impacted abortion patients and who are suffering severe illness and death from Covid-19 at vastly disproportionate rates, Kaye added.

Indeed, back in April, as ARC-Southeast was working to help patients secure abortion access during the worsening pandemic, Njoku recalls reading about the staggering impact the virus was having on Black people; in Georgia alone, they accounted for 80 percent of those hospitalized with Covid-19. I was like, yall, this is the great unraveling thats happening in our society, she said.

In July, a district judge in Maryland agreed with the medical experts and issued a preliminary nationwide injunction blocking enforcement of the in-person requirements during the pendency of the case. The Trump administration balked and asked the 4th U.S. Circuit Court of Appeals to lift the stay; that request was denied.

But instead of allowing the case to play out, the Trump administration asked the Supreme Court to intervene. Given that surgical methods of abortion remain widely available, the enforcement of longstanding safety requirements for a medication abortion does not constitute a substantial obstacle to abortion access, the administrations petition reads, even if the Covid-19 pandemic has made obtaining any method of abortion in person somewhat riskier.

Attempts to truncate the normal course of litigation by running directly to the Supreme Court and forcing cases onto the so-called shadow docket has become a hallmark of the Trump administration, even though it is a move that is supposed to be reserved for extraordinary circumstances. In deciding these cases, the court often issues an order without the full facts before it, without hearing arguments, and without issuing opinions. It typically offers no explanation for its reasoning, even when dissenting justices voice serious objections, and even when the court is effectively overturning the unanimous decisions of lower courts, David Cole, the ACLUs national legal director, wrote in the Washington Post. In the case of the medication abortion challenge, the court could effectively ensure a higher risk of viral transmission with the stroke of a pen.

After pending on the docket for about six weeks, the Supreme Court finally weighed in on October 8, allowing the stay to remain in effect at least for now. In a short order, the court sent the question of whether the stay should be lifted back to the Maryland court for further consideration, essentially postponing any action until after the November election. Justice Samuel Alito, joined by Clarence Thomas, penned a dissent saying that the court should have granted the administrations request.

Had the court granted that request, Kaye said, it would have sent a chilling signal about what lies ahead with a post-Ginsburg court. And though the courts decision to stay out of this particular abortion fight at this particular moment is certainly a win for patients in the short term, she added, its hardly an indication that the right to abortion is secure.

As the pandemic raged this spring, Dr. Honor MacNaughton worried about her patients. MacNaughton, a plaintiff in the ACLU case, is a family physician working in a safety-net hospital system in the Boston area. Her patients are mostly lower-income and people of color, groups disproportionately impacted by the virus. As our health care system was closing down to in-person visits, and we were trying to do everything we could to limit exposure to the virus, it seemed so wrong to require people to still come, in person, to pick up a medication, she said.

Shed long known that the REMS was problematic and that two decades of data demonstrated the safety of mifepristone for pregnancy termination and miscarriage management. I think from a medical standpoint, theres enough evidence for us to feel really confident that the in-person visit isnt required, she said. Since the Maryland court issued its injunction, providers across the country have, for the first time, been able to provide the medication without that constraint. Being able to provide this care since the injunction has been a ray of hope, MacNaughton said. Its given me a glimpse into what more equitable or stigma-free care could look like.

Kirsten Moore, head of Expanding Medication Abortion Access, which was created in part to push for the REMS to be rescinded, has long known that medication abortion is burdened by unnecessary restrictions. She was formerly head of the Reproductive Health Technologies Project, which was founded in 1988 to help bring medication abortion to the U.S. and later successfully pushed for emergency contraception, also known as the morning-after pill, to be made available over the counter.

When medication abortion was approved by the FDA in 2000, Moore said that advocates assumed the restrictions would be revisited as safety data developed. That has not happened. Were still jumping through the same hoops today that we had to when it was first approved, she said. That doesnt make sense, right?

Yes, Roe v. Wade is a great gift. It made abortion legal, but the reality is that it did not make it accessible.

For both Moore and MacNaughton, the disconnect between science and public policy demonstrates that the REMS is about something else altogether a solution in search of a problem.

Of course, the same could be said about most restrictions on abortion access. Lawmakers often peddle these restrictions, like the hospital admitting privileges requirement, as a way to ensure patient safety, even though the alleged benefits fail to materialize. Forty-four states have passed one or more restrictions on abortion access. Twenty-six states mandate delays for patients seeking care; in South Dakota, the 72-hour waiting period doesnt include weekends or state holidays, so a patient could end up having to wait a week before being seen. Thirty states mandate pre-abortion counseling and many incorporate junk science, including, for example, that abortion leads to a greater risk of breast cancer. Several states require providers to counsel patients that medication abortion can be reversed, even though there is no sound science to back up this claim. Taken together, these restrictions have made abortion all but inaccessible across a wide swath of the country, often forcing women to travel long distances across state lines to receive care.

For those who live in the six states served by ARC-Southeast Alabama, Florida, Georgia, Mississippi, South Carolina, and Tennessee these struggles are common. Every single one of those states experiences some level of reproductive oppression, whether it comes from the legislature or just ideas of shame, stigma, and fear around abortion, Njoku said. She notes that her clients face obstacles to accessing all kinds of basic health care services. None of the states has had any sort of Medicaid expansion; roughly half of Georgias 159 counties are without an OB-GYN. These are all the things that weve always had to navigate, she said. Yes, Roe v. Wade is a great gift. It made abortion legal, but the reality is that it did not make it accessible.

And since Trump took office, lawmakers in states hostile to abortion rights have taken more direct aim at the heart of Roe and its promise of the right to pre-viability abortion.

Women wearing costumes from The Handmaids Tale protest in front of the Alabama State House after the state Senate passed HB314, whichwould ban nearly all abortions, on May 14, 2019, in Montgomery, Ala.

Photo: Elijah Nouvelage for The Washington Post via Getty Images

In 2019 alone, Georgia, Kentucky, Louisiana, Mississippi, and Ohio all banned abortion beginning at six weeks the point at which fetal cardiac activity can be detected and long before many people even know theyre pregnant. Alabama went a step further, passing a law that would ban nearly all abortion. Missouri passed a law to ban abortion at eight weeks, while both Arkansas and Utah have banned abortion at 18 weeks.

Other states have passed bans that interrogate a persons reason for seeking an abortion and would bar access if its based on the sex or race of the fetus or on a diagnosis of Down syndrome or other fetal abnormality. A district court in Missouri has blocked that states anti-discrimination law banning abortion based on a Down syndrome diagnosis, but on September 24, the states solicitor general told a panel of the 8th U.S. Circuit Court of Appeals that the law should be allowed to go into effect in part because individuals with Down syndrome are on the brink of complete elimination.

Since 1973, in Roe v. Wade, the court has given the right to the individual to decide whether or not they want to choose to become a parent at that point in time, said Helene Krasnoff, vice president of public policy litigation and law at Planned Parenthood Federation of America. These laws literally fly in the face of that, she said. They represent another way in which the Supreme Court can really undermine the protections that we have enjoyed, and that Ruth Bader Ginsburg upheld for so many years, without actually outright overruling Roe.

Currently, there are 17 abortion-related challenges to various state restrictions pending in federal appeals courts or before the Supreme Court.

Nothing about the growing storm around reproductive rights is new to Njoku. A lot of folks have been talking about this post-Roe reality, she said. Thats an actual lived reality in states like Texas and Mississippi and really the states we work in in the Southeast. Weve been preparing for things like this because weve been living in this context.

ARC-Southeast has received nearly 16,500 requests for support since they began operations in the summer of 2016. More than 60 percent of clients are already parents. From July 2019 through June 30, ARC-Southeast provided nearly $450,000 in abortion funding and practical support. As the pandemic has continued, jobs have been lost, and politicians across the country have tried to use the public health crisis as a pretext to further block abortion access, Njoku saidthe organization has provided funding not only for abortion, transportation, and lodging, but also for car repairs, food, and even masks. Njoku has seen patients from Texas, Louisiana, Kentucky, and West Virginia come to her region for care, and ARC-Southeast has helped patients to travel as far away as New Mexico, Colorado, and Maryland to get the care they need.

Njoku has been encouraged not only by the donations coming in to support ARC-Southeasts work, but also with a seeming awakening among many that abortion rights have to be viewed within a larger framework that a right without access means nothing, and that people of color are disproportionately impacted by lack of access to basic health care and the racism built into many of the nations social systems. The future that were fighting for is more than just whether or not abortion is legal, she said.

Theres no doubt that the nomination of Barrett presents a threat to that future. According to an analysis by the Center for Reproductive Rights, Barrett has signaled that she believes the Supreme Court should weigh in on the legality of banning abortion based on a patients reason for seeking it, and has suggested that abortion restrictions should be allowed to take effect while questions about their legality are sorted out in court. In Texas, the restrictions ultimately struck down by the Supreme Court were initially allowed to take effect, leading to widespread clinic closures; many never reopened.

And while the Affordable Care Act for the first time created gender parity in health coverage and opened access to maternity care and no-cost birth control, Barrett has expressed skepticism about the legality of the law. In 2012, she signed a letter opposing the ACAs birth control mandate that called contraception and sterilization gravely immoral and unjust and incorrectly described the morning-after pill as an abortion-inducing drug.

Still, Njoku is steadfast in her determination to press forward. Even in the midst of so much pain and so much trauma, she said, in the midst of all of this, we still have people who are willing to continue doing this fight no matter what.

Read more from the original source:
The Fight for Reproductive Justice in a Post-Ginsburg World - The Intercept

Comments Closed|

Life was hell but our GPs didnt believe we had started menopause in our 40s – The Sun

October 13th, 2020

WILDLY fluctuating hormones mean hot flushes and zero desire for sex are often just the tip of the iceberg when it comes to The Change.

The menopause usually occurs between the ages of 45 and 55 but symptoms can start years before periods stop a time of transition known as perimenopause.

5

Subtle changes in mood or menstrual cycle, trouble sleeping and pain during sex can all be early signs.

Yet for many women, symptoms are mistaken for common illnesses. Ahead of next Sundays World Menopause Awareness Day, we speak to three women who were driven to despair in their forties by their misdiagnosed menopause.

SITTING on her bedroom floor sobbing, Jo Morcom told her husband Paul she wanted it all to stop.

The mother of three had convinced herself her family would be better off without her.

5

For more than a year Jo, 46, had been back and forth to see her GP, complaining of migraines and terrifying loss of memory.

Looking back, she says: As time went on, I slowly turned into someone I barely recognised.

Yet, despite repeatedly asking if her hormones were to blame, Jo says she was dismissed. She was referred for a brain scan and when that was normal she was told it was just her chronic fatigue syndrome.

Eventually Paul, 51, booked an appointment. This time he went with Jo and they refused to leave the clinic until doctors agreed to give a blood test.

The results confirmed that Jo, who also lives with chronic fatigue syndrome, was undergoing the early stages of menopause.

Experts warn that many women similarly get an inaccurate diagnosis failures that cost the NHS millions of pounds in repeat appointments, while also ruining patients lives.

Dr Louise Newson, a GP and menopause specialist, says a survey of 5,000 women showed one in three had to wait at least three years before getting a diagnosis.

She says: I constantly hear from thousands of menopausal women how they are misdiagnosed with conditions such as fibromyalgia, migraines, depression, cystitis, IBS and chronic fatigue, when no healthcare professional has considered their menopause or perimenopause as the underlying cause of their symptoms.

There is currently no formal menopause training for doctors and nurses, she says a situation that must change.

Diane Danzebrink, a psychotherapist and menopause expert, echoed the call.

She says many women are forced to pay for costly private care, resorting to credit cards and loans to pay for help they should be getting on the NHS.

Ms Danzebrink says: Women are regularly told they are too young to be menopausal and this has to stop.

Doctors need to listen to women, who know their own bodies better than anyone, and stop telling them their symptoms are all in their heads.

"This is costing women their health and wellbeing, sometimes their jobs and relationships. And it costs the NHS a fortune in repeat appointments and referrals.

For Jo mum to daughters Helana, 24, and Cate, 16, and 12-year-old son Stanley the alarm bells started to ring months earlier, while heading to her home in Broxbourne, Herts, following a night out.

She had driven the route dozens of times before but that night she got completely lost.

For Jo, a personal assistant, memory loss was the latest addition to a long list of symptoms that had started to creep in five years previously. Debilitating migraines came first, followed by brain fog, joint pain and chronic fatigue.

Over the course of 13 months and numerous visits to her GP, Jo tried to convince the doc her symptoms were hormone-related.

5

She says: When I couldnt find my way home that night, I knew there was something terribly wrong. I could have driven that route with my eyes shut.

I knew it so well, which is why it was terrifying.

Jo was 41 when she started to suffer horrendous migraines that floored her for days.

She says: I would get halfway to work then have to turn around and head home because I felt so ill.

My periods were irregular too, so it was in the back of my mind that it could all be linked. Over the following months, Jo made several further appointments with her GP. She was prescribed medication for the migraines and referred for an MRI scan.

Jo says: At no point did anyone ask me about my menstrual cycle and any other symptoms.

The scan checked for brain and pituitary tumours but when it came back normal, I was diagnosed with chronic fatigue syndrome. Each time I tried to bring up the subject of hormones it was dismissed.

I couldnt sleep despite being exhausted, and my body ached all over. I looked and felt unwell.

I started looking at menopausal symptoms online and went back and forth to doctors trying to get them to listen. Time and again, each said I was too young.

Paul and the kids walked on eggshells around me. I knew I was being intolerant but I couldnt stop myself. I detached myself from family and friends, which was so unlike me.

I asked for blood tests to check my hormone levels but I was made to feel like I was time wasting and being dramatic.

Things came to a head the day Paul, a domestic appliance engineer, found Jo sobbing in the corner of their bedroom.

She says: I couldnt cope any longer and started thinking how much easier it would be for everyone if I wasnt around any more. I just wanted it all to stop.

After demanding her blood test, Jo finally had her answer.

My oestrogen and progesterone levels were completely out, she says. I felt angry that I had suffered for so long.

It should not have taken that long to get the right help. I had an idea all along.

I know my body better than anyone.

Since then Jo has switched GPs and she reckons her new doctor is fantastic.

She takes the gel form of HRT and an antidepressant, which has helped her get back on track.

She says: While I am relieved to finally get a diagnosis, things need to change.

Women shouldnt need to put up a fight to get help or be ashamed or embarrassed of the menopause.

Talking openly and honestly about it is so important.

WHEN Maria Rooneys doctor suggested she might be pregnant aged 46, Maria laughed.

The Nottingham social worker and mother of two had booked an appointment after her periods had become increasingly unpredictable.

5

Shocked at the doctors suggestion, Maria, now 49, agreed to take a pregnancy test.

She says: I knew I couldnt be pregnant because I had the contraceptive implant and had lots of other symptoms.

I was constantly exhausted and extremely short-tempered. Until then I had been a good sleeper, but I laid awake most nights. I went from being a confident and happy person to feeling low and anxious.

She finally saw a doctor in February 2017. Her own mum had gone through early menopause meaning Maria recognised the signs in herself.

Even so, she says: I didnt believe it. I thought menopause happened to women in their fifties and sixties.

When the pregnancy test came back negative, I asked if I might be going through early menopause.

The doctor looked at me like I was being ridiculous. She said I was far too young for that.

Over the following year, Marias symptoms went from bad to worse.

She says: Id forget peoples names and had to leave a job I loved. Still, nobody could give me any answers.

Nobody was listening to me, which was really frustrating. I felt like I was falling apart.

I did my own research and took what I found back to my GP.

After 18 months, I was referred to an NHS menopause clinic and given HRT tablets.

Although Im still adjusting to the medication and trying to get the dosage right, I feel relieved Im on the right path.

When I look back now, I feel angry. I suffered for so long but all I wanted was for someone to listen.

Women need to stick up for themselves and if theres something wrong, they must be listened to.

WEIGHT gain, hot flushes and low moods left Vicki Leaver a nightmare to be around, she says.

Now 41, Vicki ticked almost every box for symptoms of perimenopause yet her GP offered her antidepressants, blaming her unhappiness on lockdown.

5

The admin assistant, who lives in Perth with son Dylan, 18, and daughters Lily, six, and Jasmine, three, says: As soon as I turned 40, everything went wrong. It felt like an extreme case of PMT, but I was grumpy and snappy every day.

Feeling low and hopeless took over my life but I had no idea why I felt that way. Everyday tasks like dealing with a sink full of dirty dishes or an untidy house became too much.

Dylan took the brunt of my bad moods, which made me feel incredibly guilty. I once spent the entire school run crying.

Id wake in the night dripping in sweat and I struggled to hold a conversation because Id forget certain words.

Her periods changed too. Some months they were short and light. Other times, she would bleed so heavily she couldnt leave the house.

She continues: I made an appointment with my GP and broke down, explaining how I was feeling.

HOUSE THATEstate agents share most bonkers listings such as loo made to look like a THRONE

HEADED WESTArrogant Dominic West & wife put on toe-curling display of denial with kiss

FAT'S NOT OKNew mum shares fat-shaming leaflet NHS sent seven weeks after she gave birth

NAKED AMBITIONDoes the frock say fame... or just lame? We rate celebs' nearly naked looks

Live Blog

SELLING SUSSEXAnger as guests forced to pay 1.3k EACH to see Meghan speak at women summit

MOUSE HUNTPrimarks Xmas Disney range has landed & has baubles & cosy blankets from 2

But I got nowhere. I had blood tests that all came back normal, so I was prescribed the progesterone-only Pill to help with my heavy periods. The doctor suggested I was probably depressed because of lockdown and offered antidepressants.

But it was much more than just low moods and I wanted to get to the root of the problem, so I refused. I looked up perimenopause online and except for UTIs, which are common when hormone levels drop, I ticked almost every box.

Since January, I have talked to four different doctors and in June, I started HRT. Four months on, I feel like a different person. I wouldnt wish the last couple of years on anyone.

On Call with Dr Zoe

WHEN a woman will go through the menopause is largely predetermined before she is even born.

Thats because we are born with all our eggs. When they drop below a certain number, you are deemed to be in menopause. But how can you tell?

The best and first thing to do is speak to your mum. It is the biggest clue you have. If she went through it early, you are more likely to follow suit.

Its not an exact science but a good indication. The earlier you know, the better prepared you can be.

A good friend of mine, Zoe Hardman, recently shared her experience of facing the menopause at just 37 with Fabulous. It was only when her older sister discovered that she was menopausal aged just 34, while trying to get pregnant that they spoke to their mum and discovered that she had been through early menopause.

After openly talking about it she said she received so many messages from other women in similar situations, women who shared the shame they had felt.

No woman should feel any shame about facing menopause, whatever her age.

Its so important we all speak about it, to break the taboo and destigmatise something that is completely natural and happens to every woman.

Shame and stigma can be a barrier to women getting the right support and the right treatment. If you are under the age of 45 and start to notice you are suffering with symptoms you think are linked to menopause, it is really important you speak to your doctor.

Appointments with your GP are a partnership. We might have the knowledge but YOU know how you feel. You know when something is not right.

The important thing is to be straight with us. Dont just come in, describe your symptoms and leave it hanging. If you think you are suffering menopausal symptoms, tell us.

Unfortunately, the signs and symptoms of perimenopause and menopause are very similar to lots of other common conditions that affect women in their late thirties and early forties.

Gut feeling

Read more from the original source:
Life was hell but our GPs didnt believe we had started menopause in our 40s - The Sun

Comments Closed|

Stars who have frozen their eggs – Nicki Swift

October 13th, 2020

Olivia Munn opened up about freezing her eggs during an interview for the Anna Faris is Unqualified podcast in 2016, saying that she did it because her friend found out she "had the egg count of a 50-something-year-old woman." Munn decided to visit a doctor herself, and while she was told she has "a lot of eggs," she was also told that she might as well freeze some of them so that she would always have them available.

The star also talked about turning 35, saying that's when "you're high risk." However, "many doctors are quick to discount the belief that age 35 always and instantly draws a line between a healthy pregnancy and a high-risk one," according to Self. Indeed, Sarah J. Kilpatrick, M.D., Ph.D., chair of the department of obstetrics and gynecology at Cedars-Sinai, told Self, "I would never tell someone that just because she's 35 she has to see a high-risk doctor only if there's something in her history or something that happened during her pregnancy that warrants it."

That may be true, but Munn clearly still feels confident in her decision. "I think that every girl should do it. ... [For] one, you don't have to race the clock anymore. You don't have to worry about it," she told the former Mom star and podcast host. "Doomsday is now like 'whatevers day,' because I am prepared."

Original post:
Stars who have frozen their eggs - Nicki Swift

Comments Closed|

Breast Cancer Awareness 2020: Carol Keton Parsons: Testing and support are key – The Salem News

October 10th, 2020

Name: Carol Keton Parsons

Age: 79

Hometown: Born in Manchester-by-the-Sea, grew up and currently lives in Gloucester

Background: Married with three daughters, graduated from Gloucester High School and took psychology courses at North Shore Community College in Danvers, grew up at Hillcrest Nursing Home as her parents owned the facility, is a Daughter of the American Revolution, loves the local museums and library.

Favorite childhood memory: My grandmother lived on Centennial Avenue, and she would make homemade old-fashioned doughnuts. I can still see her standing there making doughnuts.

Experience with breast cancer: When Parsons felt a lump in her breast while taking a shower at the age of 69, she knew something was not right. That same week, she went to a cancer clinic, where an ultrasound confirmed her fear. The doctors diagnosed her with invasive ductal triple-negative breast cancer.

All breast cancer is serious, but they said this was an aggressive kind of cancer where you dont live very long, Parsons said.

A doctor in Gloucester suggested that Parsons pursue chemotherapy, which she ended up doing every other day for three weeks.

After finishing up her chemo treatment, Parsons was given radiation treatment at Massachusetts General Hospital and had a lumpectomy to remove the cancer from her breasts.

The Gloucester resident is now 10 years cancer-free.

What she wants people to know: First, older women should get tested. A lot of women who are my age dont think they can get it, she said.

Secondly, go to the support meetings for those who have breast cancer. For Parsons, the bond with other women who have or had breast cancer is a strong one. When she would see other women in head scarves, she would go up and hug them.

When you have breast cancer, it is like a bond, she said. Everyone hugs everyone.

What Is triple-negative breast cancer?

Triple-negative breast cancer is a kind of breast cancer that does not have any of the receptors that are commonly found in breast cancer.

Think of cancer cells as a house. The front door may have three kinds of locks, called receptors.

One is for the female hormone estrogen.

One is for the female hormone progesterone.

One is a protein called human epidermal growth factor (HER2).

If an individuals cancer has any of these three locks, doctors have a few keys (like hormone therapy or other drugs) they can use to help destroy the cancer cells.

But for those people who have triple-negative breast cancer, it means those three locks arent there. So the keys doctors usually use wont work. But chemotherapy is still an effective option.

Often, patients first need to have the lump removed (a lumpectomy) or the entire breast removed (a mastectomy). Then, they have chemotherapy treatments to target any cancer cells that cant be seen cells remaining in the breast or that may have spread into other parts of the body. Sometimes doctors recommend chemotherapy before surgery to shrink the cancer.

Source: Centers for Disease Control and Prevention

We are making critical coverage of the coronavirus available for free. Please consider subscribing so we can continue to bring you the latest news and information on this developing story.

More:
Breast Cancer Awareness 2020: Carol Keton Parsons: Testing and support are key - The Salem News

Comments Closed|

Not just a survivor a ‘thriver’ – Record Herald

October 10th, 2020

Girls Night Out is an annual breast cancer education event for women hosted by Fayette County Memorial Hospital (FCMH) and Tanger Outlets Jeffersonville, and recently a previous honoree and breast cancer thriver, Dianna Hawes, shared her story.

Although a local breast cancer fighter or survivor is honored each year, this year the event was unable to occur due to the pandemic. Dianna was honored in 2018. All attendees that year released pink balloons to lift Dianna up in her journey.

Diannas story was shared with the R-H from FCMH as a testimony to the impact Girls Night Out has on its honorees and the relationships and support groups that are built out of the event.

In addition to the impacts the event has on the honorees and relationships between participants, it includes breast cancer education. Participants in the Girls Night Out can visit displays from local businesses and get health education information from FCMH and FCMH partners.

Diannas story:

My name is Dianna Hawes, and I am a breast cancer thriver.

Theres a lot of discussion around being called survivors versus thrivers. I personally prefer the latter. Why? Because cancer has not defined me because cancer is lowercase in my life because cancer was a valley to be crossed and not a mountain range to be abandoned.

But how do I use this aggressive adjective so confidently? Because of the broad support of both friends, family and strangers.

You see, I had made a big decision the day before the 2018 Girls Night Out Breast Cancer event. A decision that was met with great opposition from my husband and close friends.

I had decided that after three chemo treatments, I was done.

It was too much, I said.

I knew God was present in the deepest part of the valleys, but I felt weak and defeated.

In May of 2018, I had my annual mammogram. Having hardly ever gone to a doctor for any reason, I was stopped in my tracks when I was told I needed to return for further testing. Next was the biopsy, and at last, the diagnosis. Triple positive breast cancer rare and aggressive.

A very small tumor probably not in lymph nodes, along my chest wall and couldnt be felt.

Choices had to be made. Lumpectomy or mastectomy? Keep surgeon or get another opinion? Genetic testing or take a big guess?

After genetic testing showed only one possible issue and three second opinions, a lumpectomy it was. I was told I probably would just need radiation afterwards.

But when my best friend greeted me as I awoke from surgery, I knew things had changed. There were cancer cells in my lymph nodes the game changer.

Four types of chemotherapy every three weeks, then six weeks of radiation. So again, another very important choice whether or not to put on my big girl panties and do what needed to be done, or to crawl into the nearest hole and deny the inevitable.

I guess, in hindsight, there wasnt much of a choice. My family and friends seemed to take that away from me, and the treatment began late summer.

I continued to work off and on throughout it all, and I found this to be a source of strength of sorts. My co-workers were amazing in their support.

Sometimes it appeared those around me were fighting harder than I was for myself. Chemo places you in a very wonky place.

People would ask how I was feeling. The only word that made sense was wonky. During the lowest days and nights, I could do nothing but whisper the name of Jesus. But this was enough. His presence was overwhelming, and I pursued the goal.

But after the third treatment and stuff going on in the family, I lost my steam my will. But I had been given the incredible opportunity to be honored at the Girls Night Out event. So I put my big girl panties back on and went. Little did I know, it was a God appointment that He scheduled and planned.

During the event, one stranger after another approached me. Most were thrivers, some of 2 years and others as much as 32 years.

They were not only encouraging me to thrive, they were also offering to drive me to treatments, to provide my family with meals, to share hats with me and more. Strangers yesterday, sister thrivers that day.

You see, I had to keep going. I had to do it for me, for them, for those who would follow me. I had to do more than survive. I HAD TO THRIVE and live life abundantly.

That event was the real game changer, and I will always be grateful for those who chose me to be honored.

Dianna was not the first nor will she be the last to be diagnosed with breast cancer in Fayette County. Breast cancer is the second most prevalent type of cancer seen in Fayette County. Nationwide, one in eight women will be diagnosed with breast cancer in her lifetime.

Likewise, it is the second most prevalent type of cancer that is being treated at the FCMH Cancer Care Clinic even though the clinic has only been open about a year.

The clinic is in collaboration with Adena Health System and Dr. Shylaja Mani, and is now able to provide chemotherapy, immunotherapy and hormone therapy. Residents no longer have to leave the county to receive these vital treatments.

Early detection through regular mammograms is key to fighting breast cancer. The National Breast Cancer Foundation reports that 64 percent of cases are diagnosed at a localized stage meaning there is no sign that cancer has spread outside the breast. When this early diagnosis is made, the five-year survival rate is 99 percent.

In conjunction with the FCMH Womens Wellness Center providers Emily Stephens, CNP and Dr. Loliya Idoniboye and the FCMH radiologist Dr. Michael Barrows, the FCMH team is here to support patients from diagnosis through treatment.

Local breast cancer thriver and 2018 Girls Night Out honoree Dianna Hawes.

Dianna Hawes shares her experiences with breast cancer

Read the rest here:
Not just a survivor a 'thriver' - Record Herald

Comments Closed|

Puma’s Positive Neratinib Data, And Other News: The Good, Bad Ugly Of Biopharma – Seeking Alpha

October 10th, 2020

Puma Biotechnology reports positive Neratinib Phase III data

Puma Biotechnology Inc. (PBYI) reported efficacy data for neratinib from the Phase III ExteNET trial. The study involved patients with HER2-positive, hormone receptor-positive (HR+), early-stage breast cancer. The primary endpoint of the trial was invasive disease-free survival. The key secondary endpoint was overall survival. The drug candidate is already approved in the European Union for patients with HR+ breast cancer who initiated treatment within one year of completing an adjuvant trastuzumab-containing regimen.

ExteNET was a multicenter, randomized, double-blind study. It involved 2,840 patients with HER2-positive eBC who were given neratinib after neoadjuvant and/or adjuvant therapy with chemotherapy and trastuzumab. The patients were classified according to their hormone receptor status. The patients were then randomized to be administered either oral neratinib 240 mg/day or placebo for a year.

The data showed that for the HR+ /< 1-year patient population, the absolute 5-year invasive disease-free survival benefit versus placebo was 5.1 percent. The absolute 8-year overall survival benefit was reported to be 2.1 percent. The 5-year cumulative incidence of CNS metastases was at 0.7 percent in the neratinib arm and 2.1 percent in the placebo arm. For the HR+/ <1 year, no pCR subgroup of patients that were at a high risk of disease recurrence, the absolute 5-year iDFS benefit in the neratinib cohort versus placebo was found to be 7.4 percent.

Professor Arlene Chan, Vice Chair Breast Cancer Research Centre - WA, said, This newly published study provides consistent and durable benefits of neratinib in a subset of HER2-positive early stage breast cancer patients who are considered to be at greater risk of relapse: namely patients with HR+ tumors that did not achieve a pCR after neoadjuvant treatment (no pCR). The benefits demonstrated are meaningful in all endpoints evaluated, including iDFS, OS and CNS recurrence, and thus should help guide future clinical decisions.

The data showed that the most common grade 3 adverse events included diarrhea, vomiting and fatigue.

Puma Biotechnology is a biopharmaceutical company. It is mainly engaged in developing and commercializing products in the cancer segment. The company in-licenses the global development and commercialization rights to PB272, the oral neratinib, as well as to PB272 and PB357. PB272 also goes by the name of intravenous neratinib. The oral version of the drug was approved by the FDA for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy in 2017. It is marketed in the United States market under the brand name of NERLYNX in the tablet form.

NERLYNX was given further approval for treating adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting in February 2020. For this indication, the drug had been approved to be used in combination with capecitabine. The drug has been given marketing authorization by the European Commission for specified conditions.

Investment Thesis: The stock has remained steady in the recent past, making it suitable for even conservative long-term portfolios. The latest news and the upcoming catalysts are expected to provide a positive fillip to the stock price.

Y-mAbs Therapeutics Inc. (YMAB) reported that the FDA has delivered a Refusal to File letter with regard to its Biologics License Application for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma. The BLA was submitted in August, 2020.

The letter states that the FDA requires further details pertaining certain parts of the Chemistry, Manufacturing and Control module and the Clinical module. However, the regulator has not requested or required any additional non-clinical data. The company stated that it is confident about addressing all points raised by the FDA. It also believes that it can provide the requested additional CMC information.

Y-mAbs plans to submit supplementary data from Study 101. This data includes tumor response data from patients with evaluable disease among the first 24 patients included in the protocol. The company intends to request a Type A meeting with the FDA. It is also looking to work with the FDA to make appropriate amendments to the BLA. Y-mAbs intends to file the reworked BLA before the end of this year.

Y-mAbs is a late-stage clinical biopharmaceutical company. It is mainly focused on developing and commercializing novel, antibody-based therapeutic products for treating cancer. The company has robust development pipeline with two pivotal-stage drug candidates. Out of these, naxitamab is designed to target tumors which express GD2, while omburtamab targets tumors expressing B7-H3.

Despite this setback, the company also reported a positive news, as its leading bispecific antibody program nivatrotamab for the treatment of neuroblastoma was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA.

Investment Thesis: The stock is currently trading close to its highs. Coupled with the latest setback, it is advisable to watch this stock for further development and some meaningful pullback in the price.

Halozyme Therapeutics Inc. (HALO) announced that it has expanded its collaboration and licensing agreement with Argenx. The collaboration deals with the companys Enhanze technology, and the original agreement was signed in February 2019.

The new terms of the agreement provide for Argenx to have an exclusive access to Halozymes Enhanze drug delivery technology for three more targets. The company now can name up to six targets under this collaboration. Dr. Helen Torley, president and chief executive officer of Halozyme, Argenx has made rapid progress in the clinic with efgartigimod utilizing ENHANZE since signing the original agreement, moving to a Phase 2 study initiation for an indication being developed only as SC, within just fourteen months.

So far, Argenx has named two targets for this program. These are human neonatal Fc receptor FcRn and complement component C2. The company can access Enhanze for its FcRn antagonist efgartigimod, its late-stage development for several severe autoimmune diseases.

Halozyme is a biopharmaceutical company. Its Enhanze technology is designed to make various treatments more efficient and time-effective. The technology is based on its proprietary enzyme, rHuPH20. It is mainly used for effectual delivery of injected drugs and fluids with the aim of reducing overall treatment burden. The company has licensed this technology to a number of major biotech and pharma companies, including Alexion (ALXN), Lilly (LLY), Janssen (JNJ) and Pfizer (PFE), among others. Its revenue stream consists of royalties and milestone payments received from such collaborations.

Investment Thesis: The company has strong potential ahead with its robust collaboration framework. However, the stock is currently trading at highs and may see some correction in the near future, providing an opportunity to build a position.

Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.

That means that when the catalyst comes that will make or break a stock, weve positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Visit link:
Puma's Positive Neratinib Data, And Other News: The Good, Bad Ugly Of Biopharma - Seeking Alpha

Comments Closed|

WingNuts Express opens in Magnolia and more Houston-area news – Community Impact Newspaper

October 10th, 2020

The eatery specializes in double-fried chicken wing dishes served with a variety of sauces, including buffalo, mango habanero and garlic Parmesan, among others. (Courtesy WingNuts Express)

Read the latest business and community news from the Houston area.

Tomball-Magnolia

WingNuts Express now open on Tamina Road in Magnolia

Magnolia's latest wing eatery, WingNuts Express, opened on Tamina Road on Oct. 3, according to a Facebook post from the restaurant.

Sugar Land-Missouri City

Child Advocates of Fort Bend, partners open clinic for child victims of sexual abuse

Child Advocates of Fort Bend, along with AccessHealth and the Harris Health System, opened a medical clinic dedicated to child victims of sexual abuse Oct. 1, according to a CAFB press release.

Spring-Klein

ROUNDUP: 8 businesses, restaurants that recently opened in Spring, Klein

Twisted Sisters Nutrition Shack, Fajita Pete's and Cavender's Boot City are just a few of the businesses that have recently opened in the Spring and Klein area.

Wingstop now open on Spring Cypress Road

Wingstop opened a new location at 8675 Spring Cypress Road, Ste. 37B, Spring, on Oct. 8. Known for its 11 different flavors of classic wings, boneless wings and crispy tenders, the new location offers carryout and delivery services from 10:30 a.m.-midnight daily.

Cy-Fair

A Thousand Oaks Events & Retreats venue opening this month in Cypress

A new wedding and event venue, A Thousand Oaks Events & Retreats, is holding an open house Oct. 22 from 4-8 p.m. at 17011 Steinhagen Road, Cypress, to celebrate its grand opening.

Trattoria Pizza & Pasta offers Italian classics, family recipes on Cypresswood Drive

Elderin Berisha said his primary goal at Trattoria Pizza & Pasta is making customers feel at home.

If you come here on a Friday or a Saturday night, youll see all the customers know us, he said. We know their names; we talk to them; we sit with them. Its like a family. I want to try to make you comfortable when you come here. We know what you order, and we pay attention to the details.

Millennium Physicians opens new medical office in Cypress

Officials with Millennium Physicians announced the opening of a new office offering medical oncology and hematology, rheumatology and infusion services.

Heights-River Oaks-Montrose

Houston leaders react to death of transgender advocate Monica Roberts

Local leaders have joined human rights and LGBTQ organizations across the nation reacting to the loss of one of Houston's leading transgender rights advocates, Monica Roberts, who died this week.

DACAMERA chamber and jazz presenters announce virtual performance schedule

Chamber and jazz performance organizer DACAMERA announced its fall schedule Oct. 6, including a new collaboration with The Menil Collection.

Robot Noodle takes over Blackbird Izakaya spot in the Heights

Robot Noodle, a new restaurant by Delicious Concepts Group, has opened at 1221 W. 11th St., Houston, taking over the former space of Blackbird Izakaya, the group announced Oct. 7.

Pearland-Friendswood

Pearland's StrongFound Personal Training stays successful pivoting during pandemic

StrongFound Personal Training sets itself apart with its target demographic: those who are 40 years old or older.

Lake Houston-Humble-Kingwood

Millennium Physicians Internal Medicine group opens new Kingwood office

Millennium Physicians Internal Medicine group opened a new office July 15 at 22698 Professional Drive, Ste. 100, Kingwood. Internal medicine physicians Dr. Salvador Recio and Dr. Carmen Perez will be offering a variety of services at this location, including weight-loss assistance, diabetes management, well women exams, allergy testing and hormone pellet replacement.

Kelly Schafler, Emma Whalen, Adriana Rezal, Claire Shoop, Hannah Zedaker, Danica Lloyd, Matt Dulin and Haley Morrison contributed to this report.

Follow this link:
WingNuts Express opens in Magnolia and more Houston-area news - Community Impact Newspaper

Comments Closed|

Gender clinic offers ‘fairytale’ promises to children over transitioning, court hears – Telegraph.co.uk

October 8th, 2020

A transgender clinic offers "fairytale" promises to children because they are unable to give their consent to the sex-change process, the High Court has heard.

The case has been brought by 23-year-old Keira Bell, who began treatment to become a boy at 16 before later "de-transitioning", and "Mrs A", the unnamed mother of a 16-year-old girl who is on the waiting list to change gender.

They claim anyone aged 18 and under should only be prescribed hormone blockers which delay the onset of puberty with court supervision in place. Their legal action is against the Tavistock and Portman NHS Trust, which runs the country's only gender identity clinic for children.

Lawyers representing Keira Bell and "Mrs A" whose child is currently on the waiting list for treatment at the service argue that children going through puberty are "not capable of properly understanding the nature and effects of hormone blockers".

They arguethere is "a very high likelihood"children who start taking hormone blockers will later begin taking cross-sex hormones, which they say cause "irreversible changes".

Ms Bell and "Mrs A" are asking the High Court to rule it unlawful for children who wish to undergo gender reassignment to be prescribed hormone blockers without an order from the court that such treatment is in their "best interests".

At a hearing in London on Wednesday, the pair's barrister, Jeremy Hyam QC, said: "The use of hormone blockers to address gender dysphoria does not have any adequate base to support it."

He said it was "simply a fairytale" to think children of 13 or under can give informed consent to receive hormone blockers to delay puberty, adding that "a child who can't consent to any sexual activitycan't possibly give consent" to this treatment.

"We can't accept there can be an age appropriate discussion of the experiences a child has no experience of. It's just an affront to common sense to think that person is giving consent to that process," Mr Hyam said.

Children cannot properly understand the "lifelong medical, psychological and emotional implications" of taking "experimental" puberty blockers and cross-sex hormones, he told the court.

He said "the effect of hormone blockers on the intensity, duration and outcome of adolescent development is largely unknown", adding: "There is evidence that hormone blockers can have significant side-effects, including loss of fertility and sexual function and decreased bone density."

In written submissions, Mr Hyam said: "That children are not capable of giving informed consent to undergo a type of medical intervention about which the evidence base is poor, the risks and potential side-effects are still largely unknown, and which is likely to set them on a path towards permanent and life-altering physical, psychological, emotional and developmental consequences... is the common sense and obvious position."

The barrister told the courtreferrals to the NHS Gender Identity Development Service (Gids) had risen from 97 in 2009 to 2,590 in 2018, "essentially a 20-fold increase".

In a witness statement before the court, Ms Bell added: "I made a brash decision as a teenager, as a lot of teenagers do, trying to find confidence and happiness, except now the rest of my life will be negatively affected. Transition was a very temporary, superficial fix for a very complex identity issue."

However, Fenella Morris QC, representing the Tavistock and Portman NHS Trust, said the contention that children could not give informed consent to being prescribed hormone blockers was "a radical proposition".

She argued in written submissions that the claimants sought to "impose a blanket exclusion" on children under the age of 18 to be able to consent to medical treatment.

Ms Morris added the majority of children referred to Gids between March 2019 and 2020 were aged over 12, with only 13 of those referred being under the age of 13.

She argued that hormone blockers "had been widely researched and debated for three decades", adding: "It is a safe and reversible treatment with a well-established history."

Ms Morris also said the Tavistock and Portman NHS Trust referred children and young people experiencing gender dysphoria to University College London Hospitals NHS Foundation Trust or Leeds Teaching Hospital NHS Trust.

She told the court: "One cannot make a global statement that any child of any particular age is incapable of understanding these particular matters" as she reiterated "the importance of individual assessment".

She said those two trusts, not the Tavistock and Portman NHS Trust, were "responsible" for prescribing hormone blockers to children with gender dysphoria.

Lawyers representing London Hospitals NHS Foundation Trust and Leeds Teaching Hospital NHS Trust are expected to address the court on Thursday.

The hearing before Dame Victoria Sharp, Mr Justice Lewis and Mrs Justice Lieven is expected to last two days, and it is expected that the court will reserve its judgment to a later date.

The hearing continues.

Go here to read the rest:
Gender clinic offers 'fairytale' promises to children over transitioning, court hears - Telegraph.co.uk

Comments Closed|